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1. Introduction 
 
1.1 Fluoroquinolone antibacterials 
 
Quinolone antibacterials are in clinical use since 1960. The 
quinolones currently available for clinical use are 4-quinolones. 
The first two member of quinolone group are nalidixic acid (I) and 
cinoxacin (II). These agents were traditionally used for the 
treatment of urinary tract infection for many years. These drugs 
are of relatively minor significance because of their limited 
therapeutic utility and rapid development of bacterial resistance1. 
 
NN
O
COOH
CH3
CH3
 
                   (I) 
   
N
O
COOH
CH3
O
O
 
                      (II) 
 
The substitution of fluoride to the original quinolone antibacterial 
compounds yielded a new class of drugs, the fluoroquinolones 
that have a broader antibacterial spectrum and improved 
pharmacokinetic properties. 
  
Norfloxacin (III) containing fluoro group was the first member of 
fluoroquinolone antibacterial discovered in 1978 and it was also 
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the first member of the class approved for clinical use in 1986 in 
United States. Ciprofloxacin (IV) was the second2. 
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      (IV) 
 
At present many other fluoroquinolones such as enoxacin, 
ofloxacin, pefloxacin, sparfloxacin, lomefloxacin, gatifloxacin, 
moxifloxacin, and levofloxacin and trovafloxacin are in the clinical 
use. The newer fluoroquinolones have much wider spectrum of 
antibacterial activity2. Because of their safety and tolerability they 
have become popular alternatives to penicillin and cephalosporin 
derivatives in the treatment of various infections. 
 
Fluoroquinolones act by inhibiting DNA gyrase activity in the 
replication and transcription at bacterial DNA. All the new 
quinolones are effective orally and generally well tolerated. 
Development of resistance is slow.    
            
Fluoroquinolones possess excellent activity against Gram-
negative aerobic bacteria such as E.coli and Neisseria gonorrhoea 
and newer agents have better activity against Gram-positive 
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bacteria including S.pneumoniae and Staphylococcus aureus. 
They are also effective against shigella, salmonella, 
campylobacter, gonococcal organisms, and multi drug resistant 
pseudomonas and enterobacter. Norfloxacin is the weakest 
among the fluoroquinolone antibacterial. Ciprofloxacin, 
lomefloxacin and levofloxacin have excellent activity against 
Gram-negative and good activity against Gram-positive bacteria. 
Gatifloxacin and sparfloxacin have better activity against Gram-
positive bacteria especially S. pneumoniae. Moxifloxacin and 
trovafloxacin also have good activity against anaerobic bacteria. 
Ciprofloxacin (Gram-negative) and moxifloxacin (anaerobic) have 
the best activity in their respective groups3. 
 
Classification of Quinolones3 
 
The new classification of quinolone antibacterial takes into 
account the expanded antimicrobial spectrum of the newer 
fluoroquinolones and their clinical indications. (Tables 1 and 2) 
Introduced in 1997, this classification is a useful tool for 
physicians to use when empirically prescribing these drugs or 
evaluating new agents introduced to the market. Drugs in each 
group are similar in antimicrobial activity. With each successive 
generation, a significant new group of pathogens is added to the 
coverage. 
 
Ciprofloxacin, norfloxacin and levofloxacin can be taken orally to 
treat urinary tract infections and bacterial diarrhoea. Most 
fluoroquinolones are also used to treat skin, bone, intra-
abdominal, sexually transmitted diseases, and respiratory tract 
infections. However, fluoroquinolones should not be used to treat 
routine respiratory, skin, and tissue infections caused by 
pneumococci and streptococci due to resistance but instead β-
lactams or macrolides should be used. Some of the newest agents 
like trovafloxacin have proven effective against anaerobic 
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gynecological infections, intra-abdominal infections, and in the 
treatment of meningococcal meningitis1, 3.  
 
With some exceptions, agents in the 4-fluoroquinolone classes 
can also be grouped by their clinical indications. The drugs can be 
further differentiated based on available formulations, required 
dosage adjustments in renal or hepatic disease, significant 
adverse effects and significant drug interactions3 (Table 3).  
 
Toxicity with fluoroquinolones is low and they are considered well 
tolerated compared to other antibiotics. Fluoroquinolones are not 
recommended for children, pregnant or breastfeeding mothers due 
to bone development problems observed in young animals. 
Fluoroquinolones may cause phototoxicity from exposure to 
sunlight. Patients with heart disease may experience problems 
with gatifloxacin, moxifloxacin or sparfloxacin. Patients with kidney 
or liver disease may experience greater side effects when using 
fluoroquinolones. Fluoroquinolones may cause nervous side 
effects in patients having brain or spinal cord disease. Patients 
that suffer from tendonitis may have increased risk of tendon 
injury by taking fluoroquinolones3.  
 
Dose3  
 
Fluoroquinolones can be administered both orally and 
intravenously but are sometimes applied topically in solutions or 
ointments. Usually, ciprofloxacin is dosed at 500mg twice a day 
and levofloxacin is dosed at 500mg once a day. Sparfloxacin, 
lomefloxacin, gatifloxacin, and moxifloxacin are usually dosed at 
400mg once a day. Trovafloxacin is dosed at 200mg twice a day.  
Oral fluoroquinolones can be taken with a glass of water and can 
all be taken with or without food except for norfloxacin and 
enoxacin, which need to be taken with an empty stomach.  
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Combination3  
 
Although fluoroquinolones are usually effective as single agents 
against most infections, they are sometimes combined with other 
antibiotics. Oral ciprofloxacin is combined with 
amoxycillin/clavulanate in low risk febrile granulocytopenic 
patients and with piperacillin in febrile neutropenic patients. 
Another combination of ciprofloxacin or levofloxacin and 
azithromycin or doxycycline is recommended by the center for 
disease control for the treatment of uncomplicated gonococcal 
infections if chlamydial infection is a possibility.  
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Table 1: Classification of Quinolone antibacterials 
 
Generation Agents Antimicrobial 
spectrum 
General clinical 
indications 
First  Nalidixic acid 
Cinoxacin  
Gram-negative 
organisms (but not 
pseudomonas 
species) 
Uncomplicated 
urinary tract 
infections 
Second  Norfloxacin 
Lomefloxacin 
Enoxacin  
Ofloxacin 
Ciprofloxacin 
Gram-negative 
organisms 
(including 
pseudomonas 
species), some 
Gram-positive 
organisms 
(including 
staphylococcus 
aureus but not 
streptococcus 
pneumoniae) and 
some atypical 
pathogens 
Uncomplicated 
and complicated 
urinary tract 
infections and 
pyelonephritis, 
sexually 
transmitted 
diseases, 
prostatitis, skin 
and soft tissue 
infections 
Third  Levofloxacin 
Sparfloxacin  
Gatifloxacin 
Moxifloxacin  
Same as for 
second-generation 
agents plus 
expanded Gram-
positive coverage 
(penicillin-sensitive 
and penicillin-
resistant S. 
pneumoniae) and 
expanded activity 
against atypical 
pathogens 
Acute 
exacerbations of 
chronic 
bronchitis, 
community-
acquired 
pneumonia 
Fourth  Trovafloxacin 
Alatrofloxacin
Same as for third-
generation agents 
plus broad 
anaerobic 
coverage 
Same as for first, 
second and third-
generation 
agents (excluding 
complicated 
urinary tract 
infections and 
pyelonephritis) 
plus intra- 
abdominal 
infections, 
pneumonia, 
pelvic infections 
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Table 2: Indications for Quinolone antibacterials 
 
  
Indications 
 
Agents 
Uncomplicated 
urinary tract 
infections 
Nalidixic acid, cinoxacin, norfloxacin, 
lomefloxacin, enoxacin, ofloxacin, 
ciprofloxacin, levofloxacin, gatifloxacin, 
trovafloxacin  
Complicated urinary 
tract infections and 
pyelonephritis 
Norfloxacin, lomefloxacin, enoxacin, 
ofloxacin, ciprofloxacin, levofloxacin, 
gatifloxacin 
Lower respiratory 
tract infections 
(limited) 
Lomefloxacin, ofloxacin, ciprofloxacin, 
trovafloxacin 
Skin and skin-
structure infections 
Ofloxacin, ciprofloxacin, levofloxacin, 
trovafloxacin 
Urethral and 
cervical gonococcal 
infections 
Norfloxacin, enoxacin, ofloxacin, 
ciprofloxacin, gatifloxacin, trovafloxacin 
Urethral and 
cervical chlamydial 
and gonnococcal 
infections 
Ofloxacin, trovafloxacin 
Bone and joint 
infections, gram- 
negative bacterial 
infections 
Ciprofloxacin 
Infectious diarrhoea Ciprofloxacin 
Typhoid fever Ciprofloxacin 
Prostatitis Norfloxacin, ofloxacin, trovafloxacin 
Acute sinusitis Ciprofloxacin, levofloxacin, gatifloxacin, 
moxifloxacin, trovafloxacin 
Acute 
exacerbations of 
chronic bronchitis 
Levofloxacin, sparfloxacin, gatifloxacin, 
moxifloxacin, trovafloxacin 
Community-
acquired 
pneumonia 
Levofloxacin, sparfloxacin, gatifloxacin, 
moxifloxacin, trovafloxacin 
Intra-abdominal 
infections 
Trovafloxacin 
Gynecologic and 
pelvic infections 
Trovafloxacin 
Nosocomial 
pneumonia 
Trovafloxacin 
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Table 3: Distinguishing characteristics of Quinolone antibacterials 
Class and 
agent  
 
Half-
life  
 
 
Route of 
administration 
 
Dosage 
adjustment 
required  
 
Significant 
adverse 
effects  
 
Significant 
drug 
interactions  
 
First generation 
Nalidixic acid  60 to 
90 
minutes 
Oral Renal 
impairment 
  Warfarin  
Cinoxacin  1.1 to 
2.7 
hours 
Oral Renal 
impairment 
Hypersensitivity 
(fewer than 3 
percent of 
recipients) 
  
Second generation 
Norfloxacin  2.3 to 
5.5 
hours 
Oral Renal 
impairment 
  Warfarin, 
cyclosporine  
Lomefloxacin  7 to 8.5 
hours 
Oral Renal 
impairment 
Phototoxicity, 
headache (3 to 
44 percent of 
recipients), 
abdominal pain 
(11 percent), 
nausea (5.6 
percent) 
  
Enoxacin  3.3 to 7 
hours 
Oral Renal or 
hepatic 
impairment 
(patients 
with 
advanced 
cirrhosis) 
Phototoxicity 
(mild) 
Warfarin, 
ranitidine 
bismuth 
subsalicylate, 
theophylline, 
caffeine 
Ofloxacin  5 to 8 
hours 
Oral, 
intravenous 
Renal or 
hepatic 
impairment 
(patients 
with severe 
disease) 
Insomnia (13 
percent of 
recipients) 
                           
Warfarin 
Ciprofloxacin  
 
3 to 5.4 
hours 
Oral, 
intravenous 
Renal 
impairment 
Nausea, 
vomiting, 
Warfarin, 
theophylline, 
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 abdominal pain caffeine, 
cyclosporine, 
glyburide  
Third generation 
Levofloxacin  6 hours Oral, 
intravenous 
Renal 
impairment 
Headache, 
nausea (6.6 
percent of 
recipients), 
diarrhoea 
  
Sparfloxacin  21 
hours 
Oral Renal 
impairment 
Phototoxicity (8 
percent of 
recipients), QT- 
interval 
prolongation,  
Drugs that 
prolong the QT 
interval, 
including class I 
antiarrhythmics, 
tricyclic 
antidepressants, 
phenothiazines, 
cisapride 
pentamidine 
and 
erythromycin 
Gatifloxacin  7 hours Oral, 
intravenous 
Renal 
impairment 
  Same as for 
Sparfloxacin 
Moxifloxacin  12 
hours 
Oral Hepatic 
impairment 
QT-interval 
prolongation 
Same as for 
Sparfloxacin 
Fourth generation 
Trovafloxacin  
Alatrofloxacin 
7.8 
hours 
Oral 
Intravenous 
Hepatic 
impairment 
(patients 
with mild to 
moderate 
cirrhosis) 
Dizziness (2.4 
to 11 percent of 
recipients), 
severe 
hepatotoxicity 
(rare), candidal 
vaginitis (1 to 
10 percent) 
Morphine, citric 
acid, sodium 
citrate 
 
 
 
 
 
 
1.2 Aim of Present Work 
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Quantitative determination of drug is an important function of 
pharmaceutical analysis. It is involved in research activities such 
as development of formulations, pharmacokinetics, phytochemical 
studies and clinical studies. Routinely assay of raw materials and 
formulations are performed for quality assurance and quality 
control purposes.  
 
Generally selection of method of analysis depends upon the 
purpose of analysis, sample size and nature of sample. Most of 
pharmacopoeial assay of fluoroquinolones are HPLC based. 
Although HPLC methods are sensitive, selective and precise, 
selectivity of the method is limited by ability of solvent system to 
resolve constituents of the analytical sample. Moreover HPLC 
system is costly and requires costly solvents. Also maintenance 
cost of HPLC system is high. Where as UV-Visible 
spectrophotometric method of analysis require less costly 
instrument and reagents. Hence with the aim of developing cost 
effective methods for estimation of norfloxacin, ciprofloxacin and 
sparfloxacin in the present work following objectives were set. 
 
(1) To develop spectrophotometric methods for the determination 
of norfloxacin and ciprofloxacin using (a) paraldehyde and 
dichlone and (b) using crotonaldehyde and dichlone as 
chromogenic reagents.  
(2) To develop spectrophotometric method for the determination 
of sparfloxacin using Bratton-Marshal reagent. 
(3) To study effect of analytical parameters on development of 
color. 
(4) To validate the proposed spectrophotometric methods in 
terms of linearity, precision and accuracy.  
(5) To apply the proposed methods for determination of the drug 
in pharmaceutical formulations and compare the results with 
that of official or reported methods. 
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(6) To determine the concentration of sparfloxacin by the 
proposed method in the dissolution study of sparfloxacin 
tablets.  
                                                                                             Review of Analytical Reagents                           
        12        
2.0 Review of Analytical Reagents 
  
2.1 Dichlone 
 
Introduction 
 
Quinones have been employed as chromogenic agent in the 
determination of various compounds of pharmaceutical interest. 
Dichlone4,5, chloranil6, hydroquinone7,8, etc have been exploited 
as color developing reagents in the determination of amines. 
 
Chemistry of dichlone9,10:  
 
IUPAC :  2,3-dichloro-1, 4-naphthoquinone 
 Synonyms             :  Dichlone, Phygon, 2,3-dichloro-1, 4- 
    naphthalenedione 
CAS Reg. No.       :  117-80-6 
Formula                :   C10H4Cl2O2 
Structure :  
                 
O
O
Cl
Cl
 
  
Apparent color      :  Dichlone crystallize out as golden needles or  
   leaflets from alcohol. 
M.P.                     : 193°C, It sublimes. 
Solubility              : It is insoluble in water but soluble in xylene, 
DMSO and o-dichlorobenzene and is   
moderately soluble in acetone, ether, 
benzene, dioxane and DMF. 
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Dichlone has been prepared by chlorination of 1,4-
naphthoquinone11 by oxidation of 2,3-dichloro-5,8-dihydro-l,4-
naphthoquinone12 or by oxidation of naphthosulphate with 
potassium chlorate in the presence of hydrochloric acid at 0°C13. 
 
Uses 
 
Used as seed disinfectant, fungicide, insecticide and organic 
catalyst. Its LD50 orally in rat is 1.5 gm/kg. It is a potent fungicide 
and also minor dye intermediate. It is an irritant to skin, mucous 
membrane and CNS depressant14, 15.  
 
 Sensitivity data  
 
Occupational exposure of humans to dust of 2,3-dichloro-1,4-
naphthoquinone in concentration of 0.7 - 6.0 mg/m3 caused eye 
irritation16.  
 
Aquatic fate 
 
When released into water, dichlone will hydrolyze with a half-life 
of 5 days at neutral pH. Hydrolysis will be faster at alkaline pH. It 
will also be slowly photo degraded; however no rate for this 
process could be found.  
 
Atmospheric fate 
 
Dichlone emitted to the air will be largely as dust or aerosols and 
be subject to gravitational settling. It will also be subject to photo 
degradation in the vapor phase with an estimated half-life of 1.25 
hr 16.  
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Important reactions of dichlone 
 
Reaction with Thioamides 
 
Thioamides are known to exist mainly in thione form (I). 
 
S NH
R
R'
     ↔   
N
R'R
SH
      ↔   
N
R'R
S
-
 
  I            II         III 
The reaction of thioamides seems to be specific for compound 
represented by a general formula R–C (= S) NHR’ (I). In nonpolar 
medium the thio equilibrium shifts towards the thiol form (II). Thiol 
form is converted to thioenolate ion (III) in the presence of 
ammonia. Thioenolate is a strong nucleophile and remove one 
chlorine atom of 2,3-dichloro-1,4-naphthoquinone17. 
O
Cl
O
Cl
C
+
O
Cl
Cl
O
-
N
R'R
S
-
Cl
-
   
   
N
R'
O
O
Cl
S R
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Reaction with Isothiocynates  
 
Allyl isothiocynate, 4-methylthiobutyl isocynate, allylpropyl 
disulfide and diallyl disulfide are the major constituents of volatile 
oils from mustard seeds. Isothiocynate react with amine to give 
the corresponding thioureas. 
 
 
C SN
R
NH3
NH
NH2
S
R  
 
 
 
Thiourea thus formed react with dichlone to give a colored product 
on basifying the reaction mixture with ammonia18. 
 
 
Table 4: Absorption maxima of colored products obtained on 
    reacting various thio compounds with 2,3-dichloro- 
                    1,4-naphthoquinone19-25 
 
Compound Reaction medium λmax (nm)  
Thioacetamide Ethanolic ammonia 530 
Ethionamide Ethanolic ammonia 540 
INH Ethanolic ammonia 640 
Thiambutosine Ammonium acetate buffer 540
 
Methisazone Ethanolic ammonia 560 
Thiourea Ethanolic ammonia 540 
Isothiocynate Ethanolic ammonia 530 
Thiosemicarbazide Ethanolic ammonia 500 
Thiosemicarbazone Ethanolic ammonia 520 - 560 
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Reaction with Amines 
 
Buckley et al26 have studied reaction of dichlone with amines 
extensively. In their study it was found that primary and secondary 
amines reacts with dichlone to give red compounds (I) having 
absorption maxima in a range of 466 - 494 nm with an absorptivity 
of 3000 - 5000. 
O
Cl
O
Cl
O
N
O
Cl
R1
R2
NHR1
R2 ClH
        (I) 
 
Fieser27 has also described reaction of quinone with primary and 
secondary amines. 
 
The production of green or blue color from aliphatic tertiary amine 
and chloranil has been reported 28,29. 
 
Henbest30 in their study of oxidation of amine by organic oxidizing 
agent, found that reaction between tertiary amine containing a 
flexible grouping >N-CH-CH< and halogenated quinone like 
cloranil, dichlone etc. can result in dehydrogenation to enamines 
>N-C=C<. They further observed that the enamines containing a β 
C - H grouping couple with a second molecule of halogenated 
quinones to give a blue or purple dialkyl aminoquinone (II). 
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O
Cl
O
Cl
Et2NH
OH
OH
Cl
Cl
CH2
NEt2
 
 
O
Cl
O
Cl
CH2
NEt2
O
O
Cl
NEt2
 
(II) 
  
                    
The formation of the blue quinone (II) is believed to take place in 
two steps. First (a) the amine is dehydrogenated to 
diethylvinylamine. Second (b) the diethyl vinyl amine acts as a 
nucleophile, displacing chlorine from a second molecule of 
chloroquinone31. 
 
The second stage has an electronic analogy to the C-alkylation of 
β-dialkylamino crotonoic esters and cyclic enamines by alkyl 
halide32. 
 
Electron-donating methoxy groups are known to reduce the 
oxidation potential of quinones. No immediate reaction occurred 
between triethylamine and p-toluquinone, α-naphthoquinone or 
2:5-dichloro-naphthoquinone, hence it was concluded that the 
presence of halogen on the p-benzoquinone ring is necessary for 
oxidation of triethyl amine at room temperature33. 
 
Dichlone forms a stable blue complex having absorption maxima 
at 590 nm in benzene with diphenylaniline but not with triethyl 
amine.  
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Probably aromatic nucleus of amine stabilizes the complex. The 
complexes formed are reversible molecular complexes. Tertiary 
aromatic amine containing flexible >N-CH-CH< grouping, also 
gives dialkyl aminoquinone like tertiary aliphatic amine34.  
 
Tertiary aromatic amines with less hindered nitrogen gives 
relatively stable complexes, which can be isolated. Poor 
association of chloranil with hexa ethylbenzene than with hexa 
methylbenzene has been attributed to steric factors35.  
 
It has been reported that a reaction of dichlone, acetaldehyde and 
diethyl amine gave the purple compound (III, R = Et) (94 %) where 
as dimethyl amine gave also an appreciable amount of the red 
dimethylamino quinone (IV, R = Me) and less (30 %) of the 
dimethyl amino vinyl compound (III, R = Me), because nitrogen 
atom of dimethyl amine is less shielded than that of diethyl 
amine36.   
     
O
O
Cl
NR2
O
O
Cl
NR2
 
  (III)      (IV)             
 
 
 Diethylaminobutadienyl naphthoquinone (V) a blue compound 
with more extended chromophore was also prepared in 20 % yield 
by using diethyl amine, crotonaldehyde and 2,3-dichloro-1,4-
naphthoquinone with a larger amount of the product formed by 
replacement of one chlorine by diethyl amino residue. The 
presumed intermediate CH2=CH-CH=CH-NEt2 was prepared which 
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gave the same blue compound (V) in 80 % yield in 3 min at room 
temperature. It was believed that the reactions are assisted by 
complex formation between the quinone and unsaturated amine36. 
 
  
CH3
O
NH
CH3
CH3
CH2 N
CH3
CH3
  
 
                 
 
O
O
Cl
Cl
CH2 N
CH3
CH3
O
O
Cl
NCH3 CH3
 
                                           
     (V) 
 
 
In general the reactions between chloroquinone, acetaldehyde, 
and secondary amines were rapid often being complete in less 
than 10 minutes at room temperature in pure dioxane solvent36. 
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Table 5: Absorbance maxima and molar absorptivity of 
naphthoquinone in pure dioxane between 400- 800 nm36 
 
Sr. 
No 
Substitution
at C2 
Substitution
at C3 
Color λ max nm E max 
I Cl NHEt Yellow 466 30000
II Cl NMe2 Yellow 476 31000
III Cl NEt2 Red 494 31000
IV Cl OC4H8N Orange 488 42000
V H OC4H8N 
Yellow -
green 444 34500
VI Cl C2H2NMe2 Purple 558 122000
VII Cl C2H2NEt2 Violet 564 133000
VIII Cl C4H4NEt2 Blue 625 299000
 
 
 
Table 6: Variation of the Long-wave Absorption maxima of 2-
chloro- 3-(2-diethyl amino vinyl) naphthoquinone with 
Solvents.36 
 
Solvent λMax (nm) EMax 
Cyclohexane 545 12,500 
Dioxane 564 13,300 
Benzene 570 13,200 
Acetone 575 13,700 
Pyridine 575 13,000 
Propane 2-ol 585 13,300 
Nitro methane 585 13,300 
Pyridine: water 585 13,200 
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The data reveals that the absorption maxima, in visible region of 
dialkyl amino vinyl naphthoquinone, moves to longer wavelength 
(Bathochromic shift) in the usual way by increasing polarity of 
solvent. 
  
Analytical applications 
 
In analytical chemistry, dichlone has been employed for the 
detection and determination of sulphur containing compounds, 
amines and hydrazides. 
 
Compounds containing sulphydryl group, such as cysteine, 
glutathione37 etc. have been estimated using dichlone in alkaline 
media. The application of the reagent has been extended to the 
detection of thioureas18, thiosemicarbazides38, mono-
thiosemicarbazone39 and isothiocyanate19 in micro quantities. 
  
These compounds have been reacted with dichlone in the 
presence of ethanolic ammonia to give red to violet colored 
products having λmax between 500 to 570 nm. Based on this color 
reaction, a histochemical study for the localization of these 
compounds in plant tissues has been reported20. 
 
The thio group containing drugs viz. thiacetazone21, 
thiambutosin22, methisazone23, p - phenylene di isothiocynate and 
ethionamide24 have been analyzed by colorimetry in bulk and 
dosage forms using ethanolic ammonia. 
 
Dichlone has been used in the determination of INH40 and the drug 
in presence of its hydrazones 25. 
 
Piperazine41 and its salts have been analyzed using dichlone as a 
reagent. The use of dichlone in analytical chemistry has been 
reported in the determination of piperazine adipate at λmax 505 
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nm. Dichlone has been used to detect and determine aliphatic 
amines of pharmaceutical interest42. The amines have been 
reacted with dichlone in the presence of sodium carbonate to yield 
an orange-colored products having λmax at 475 nm. 
 
A spectrophotometric method has been described for 
determination of some primary aliphatic amines of pharmaceutical 
interest via reaction with dichlone. Majority of amine yielded an 
orange colored product having λmax around 475 nm. The 
pharmaceutical compounds assayed were histamine, 
norepinephrine, serotonin, neomycin, leucine, cysteine and 
isoniazid5. 
 
In a spectrophotometric estimation of primary amine with dichlone 
in presence of sodium carbonate at 65°C, aniline was found to 
give pink-purple chromogen (VI) having absorption maxima 
495nm5.  
                             
O
O
Cl
R   R = NH2 
                    (VI) 
It has also been reported that secondary amine react with 
acetaldehyde in presence of dichlone to give purple color 
compound. Acetaldehyde reacts with secondary amine to give 
Vinylamine, which subsequently attacks the halogenated quinone 
and displaces one chlorine atom to give purple compound; 2-
chloro-3-(2'-dialkylaminovinyl)-1,4-naphthoquinone (VII). The 
purple compound absorbs maximum at 564 nm in pure dioxane 
and has an absorptivity of 13,30036.  
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CH3 CHO CH3 NH CH3
     
        
                                                                     (VII) 
 
2.2 Paraldehyde 
 
Paraldehyde is polymer of acetaldehyde. Literature reveals that 
paraldehyde exists in equilibrium with acetaldehyde, 94.3% on 
paraldehyde side at 15 °C and it is used as a source of 
acetaldehyde in organic synthesis43. Acetaldehyde can also be 
obtained by heating paraldehyde at 55°C in the presence of acid 
catalyst44.  
 
  
   Paraldehyde                  Acetaldehyde 
 
Further to that paraldehyde is also stable at room temperature 
(B.P. 124.4°C). It is a colorless liquid, official in IP45, BP46, and 
USP47. It is a sedative hypnotic and anticonvulsant agent. 12 parts 
is soluble in 100 parts of water at 13°C and freely soluble in most 
of organic solvents. 
                                                                                             Review of Analytical Reagents                           
        24        
Analytical application of paraldehyde 
 
There is no evidence of use of paraldehyde as analytical reagent 
however Acetaldehyde with 2,3-dichloro-1,4-naphthoquinone has 
been used for the determination of secondary amino group 
containing drugs4.  
 
Secondary amines react with an aldehyde containing active alpha 
hydrogen to give enamines. Enamines are anionic carbon 
nucleophile and can easily displace halogen atom from a 
halogenated quinone48.  
 
The nucleophilic substitution of halogenated quinone by 
enamines results in an extended conjugated chromophore group 
to give a colored compound. 
 
Shingbal et al6 exploited the above reaction for the quantitative 
determination of propranolol and it's dosage forms, the vinyl 
amine generated is made to react with chloranil to give a colored 
compound having maximum absorbance at 640 nm.  
 
Korany et al49 utilized 2,5-dichlorobenzoquinone for color 
development in the determination of atenolol and propranolol in 
presence of acetaldehyde. The chromogen exhibits maximum 
absorbance at 645 nm. 
 
The determination of ephedrine hydrochloride and propranolol 
using acetaldehyde in the presence of dichlone in dimethyl 
sulphoxide has been reported4. The purple - blue chromogens 
exhibits absorption maxima at around 575 nm. 
 
Although the method described by earlier workers using 
acetaldehyde and dichlone is selective, it is inconvenient for 
routine analysis because acetaldehyde requires being freshly 
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prepared and also it is difficult to handle at room temperature 
(B.P. 21°C). Therefore exploitation of paraldehyde as a source of 
acetaldehyde, for the determination of secondary amines could be 
justified. 
 
2.3 Crotonaldehyde50-52 
 
Synonyms  : Beta-methylacrolein, propylene aldehyde,  
   crotonic aldehyde, 2-butenal, topanel. 
CAS No.  : 123-73-9  
Formula  : C 4 H 6 O  
Molecular weight : 70.09 
Structure               :    
CH3
O  
 
It exists in two stereo isomeric forms, cis and 
trans. Commercially available crotonaldehyde  
contains 95 % trans form53. 
Boiling point:  104˚C  
Specific gravity:  0.85 at 20˚C  
Melting point:  (-74)˚C   
Solubility: Very soluble in water; soluble in alcohol, ether, 
acetone, dimethyl sulphoxide and benzene.  
Appearance:  Crotonaldehyde is a clear, colorless to straw 
colored liquid  
Odor:   Strong, suffocating odor. 
 
It is highly flammable and produces toxic vapors at room 
temperature. Crotonaldehyde is found naturally in emissions of 
some vegetation and volcanoes; many foods contain 
crotonaldehyde in small amounts. 
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The general population can be exposed to crotonaldehyde by 
inhaling tobacco smoke, gasoline and diesel engine exhausts and 
smoke from wood burning. People working with crotonaldehyde to 
manufacture other chemicals may be exposed to higher levels. 
 
Crotonaldehyde has an irritating, pungent, and suffocating odor. 
Air odor thresholds ranging from 0.035 to 0.12 parts per million 
(ppm) parts of air have been reported.  
 
The aldol condensation of acetaldehyde followed by dehydration 
and rectification is the method generally used for the production of 
crotonaldehyde37. Commercial crotonaldehyde  (93 %) is 
stabilized with water (a solid phase separate out at 5°C).  
 
Reactivity  
 
1. Conditions contributing to instability: Heat may cause 
polymerization to occur and containers to burst.  
2. Incompatibilities: Contact between crotonaldehyde and alkaline 
materials such as caustics, ammonia, organic amines, or mineral 
acids may cause violent polymerization to occur. Contact with 
strong oxidizers may cause fires and explosions. Crotonaldehyde 
is readily converted by oxygen to hazardous peroxides and acids.  
3. Hazardous decomposition products:  Toxic gases and vapors 
such as carbon monoxide or carbon dioxide may be released in a 
fire involving crotonaldehyde.  
  
Exposure Limits 
   
As per the current Occupational Safety and Health Administration 
(OSHA) Permissible Exposure Limit (PEL) for crotonaldehyde is 2 
ppm as an 8-hour time-weighted average. The limit is based on 
the risk of eye and respiratory irritation. Exposure to 
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crotonaldehyde can occur through inhalation, ingestion, eye or 
skin contact and absorption through the skin. 
 
Summary of toxicology54-56 
 
1. Effects on Animals: The LD (50) in rats is 1,500 ppm for 30 
minutes, and the dermal LD (50) in rabbits is 380 mg/kg.  
2. Effects on Humans: Crotonaldehyde is a strong irritant of the 
eyes, mucous membranes, and skin in humans. Contact of 
crotonaldehyde with the eye may cause corneal burns. 
crotonaldehyde  exposure has not been linked to chronic effects, 
although cases of sensitization to crotonaldehyde  have been 
reported in workers.  
 
Storage  
 
Crotonaldehyde should be stored in a cool, dry, well ventilated 
area in tightly sealed containers that are labeled in accordance 
with OSHA's Hazard Communication Standard57. Containers of 
crotonaldehyde should be protected from physical damages and 
should be stored separately from alkaline materials such as 
caustics, ammonia, organic amines, or mineral acids, strong 
oxidizers, and oxygen. 
 
Uses 
 
It has been used in organic synthesis of resins and dyestuffs; as 
an intermediate in manufacture of butyl alcohol, butyl-aldehyde, 
quinaldine, crotonic acid, maleic acid, crotyl alcohol, and butyl 
chloral hydrate; solvent for polyvinyl chloride; in polymer 
technology as a reaction medium, formulator, adhesive, 
antioxidant, corrosion inhibitor, and stabilizer.  
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It is also used as sedatives, pesticides, chemotherapeutic agents 
and flavoring agents.  
  
It is as an odorant and warning agent in fuel gases. It is also used 
in leather tanning and preparation of tanning materials.  
 
It is used in manufacture of rubber and rubber antioxidants and 
accelerators; in manufacture of tear gas and chemical warfare 
agents and in photographic emulsion as a hardening agent for 
gelatin. 
 
Crotonaldehyde is an aldehyde containing alpha hydrogen that 
reacts with secondary amines to give enamines, which can be 
coupled to quinones containing halogens to produce chromophore 
with extended conjugation. Diethyl-aminobutadienyl-
naphthoquinone a blue compound with more extended 
chromophore was prepared using diethyl amine and 
crotonaldehyde37.  
 
Analytical application  
 
Analytical application of crotonaldehyde was not found in literature 
surve. For the first time in the present work it was used for 
quantitative analysis.  
 
2.4 N-(1-Naphthyl) ethylenediamine dihydrochloride 
(Bratton-Marshal Reagent) 
 
Introduction  
 
For many years an important method of analysis of sulfonamide 
has been colorimetric procedure involving diazotization of primary 
aromatic amine followed by coupling to a second component to 
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give a strongly colored diazo compound, the concentration of 
which can be measured spectrophotometricaly. The most 
satisfactory coupling agent was suggested by Bratton et al58 
(1939) and it is known as Bratton-Marshal Reagent (BMR). This 
compound is N-(1-Naphthyl) ethylenediamine dihydrochloride. 
 
Synonyms: 59,60 1,2-ethanediamine-N-1-naphthalenyl 
dihydrochloride,  
N-(1-Naphthyl)ethylenediamine dihydrochloride 
 Structure: 
   
NH
NH2
. 2 HCl
 
CAS No.:   1465-25-4 
Molecular Weight:  259  
Chemical Formula: C12H14N2.2HCl  
Appearance:  White to light tan or gray crystalline solid 
Solubility:  Soluble in water 
Melting Point:  188 – 190° C  
Caution: Harmful if swallowed, inhaled or absorbed 
through skin, Inhalation of dust is irritating to 
the upper respiratory tract. Eye contact: 
Causes irritation 
Toxicology:            Investigated as a mutagen. 
 
Analytical applications 
 
Bardelin et al61 developed spectrophotometric method for 
determination of procainamide in the range 0.5 to 25 µg/l in 
plasma using Bratton Marshall Reagent and ethanol was used to 
eliminate excess of nitrous acid.  
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Schwartz et al62 have reported practical screening procedure for 
sulfathiazole in honey using Bratton Marshall reagent. A method 
was described for rapidly screening of small samples of honey for 
sulfathiazole (ST), a drug formerly used but not approved in the 
United States for the prophylactic treatment of american foulbrood 
disease of bees. The method employed two plastic tubes arranged 
in tandem. The upper tube contained a bed of alumina, which 
removed some interfering pigments. The lower tube contained a 
very small bed of anion exchange resin in the HSO4- form, which 
trapped the ST. The drug was eventually eluted and detected 
using the Bratton Marshall reagent. Honey containing 0.1 ppm ST 
can be readily detected.  
 
Strickland et al63 have reported spectrophotometric method for 
determination of nitrate in sea water by Bratton Marshal Reagent. 
The determination of nitrate is based on reduction of nitrate to 
nitrite using a cadmium copper column. The nitrite produced was 
reacted with sulfanilamide in an acid solution. The resulting 
diazonium compound was coupled with N-(1-Naphthyl)-
ethylenediamine dihydrochloride to form a colored azo dye, the 
extinction of which could be measured in concentrations range 
concentration range of 0.05 µmol/l to 45 µmol/l.  
 
Kuchekar et al64 have reported spectrophotometric estimation of 
ambroxol hydrochloride in tablets using N-(1-Naphthyl) ethylene 
diamine dihydrochloride. The primary aromatic amino group of 
ambroxol reacted with sodium nitrite and coupled with N-(1-
Naphthyl) ethylene diamine dihydrochloride to form a pinkish red 
chromogen, exhibiting maximum absorption at 500 nm against a 
reagent blank. Beer's law was obeyed in the range of 10 to 50 
µg/ml. The recovery ranged between 100.6 and 100.3%. 
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Esteve Romero et al65 have reported determination of aniline in 
vegetable oils by diazotization and coupling with Bratton-Marshal 
reagent in a micro emulsion medium. 
 
Saltzman et al66 determined nitrogen dioxide in the atmosphere. A 
new specific reagent had been developed and demonstrated to 
absorb efficiently below 1 ppm. The reagent was a mixture of 
sulfanilic acid, N -(1-Naphthyl) ethylenediamine dihydrochloride 
and acetic acid. Color was produced with a sensitivity of a few ppb 
and stable for 10 minute. Ozone in fivefold excess and other 
gases in tenfold excess produce only slight interfering effects. 
 
Bounias et al67 have used N-(1-naphthyl) ethylenediamine 
dihydrochloride as a reagent for nanomol quantification of sugars 
on thin layer plates by a mathematical calibration process. 
 
Bratton-Marshal reagent had been used in the assay of 
Sulphacetamide sodium ophthalmic solution USP 2068. 
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3. Spectrophotometric Determination of 
Norfloxacin  
 
3.1. Introduction  
  
 Drug profile 69-71: 
 
Chemical name  :1-Ethyl-6-fluoro-1, 4-dihydro- (4-oxo-7-       
(1- piperazinyl)-3-quinoline carboxylic acid). 
 
Generic name  : Norfloxacin 
 
Molecular formula : C16H18FN3O3 
 
Molecular weight : 319.33 
 
Structural formula        :       
               
N
NH
N
O
COOHF
CH3
  
                                         
Melting point   : 227 – 228 ° C 
 
Solubility  :  Norfloxacin is soluble in glacial acetic  : 
acid. Crystallize from methylene 
chloride, methanol, slightly soluble in 
water. It is hygroscopic, in air forms 
hemihydrates. 
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Indications  
The drug is indicated in upper and lower urinary tract infections 
including cystitis, gastroenteritis from certain bacteria and 
gonorrhea.  
 
Antibacterial Actions 
 
Norfloxacin has a broad spectrum antibacterial activity against 
Gram-positive and Gram-negative aerobic pathogens. The fluorine 
atom at the 6-position provides increased potency against Gram-
negative organisms and the piperazine moiety at the 7-position is 
responsible for antipseudomonal activity. 
 
Norfloxacin act as bactericidal, inhibiting the bacterial 
deoxyribonucleic acid synthesis. At the molecular level, three 
specific events were attributed to norfloxacin in Escherichia coli 
cells: inhibition of the ATP-dependent DNA super coiling reaction 
catalyzed by DNA gyrase; inhibition of the relaxation of super 
coiled DNA; promotion of double-stranded DNA breakage. 
 
The development of resistance to norfloxacin due to spontaneous 
mutation rarely occurs. Resistance of the organism has developed 
during therapy with norfloxacin in less than 1% of patients being 
treated. 
 
Dose 
 
Usually 400 mg twice a day. The length of treatment depends on 
the problem. For example, uncomplicated cystitis is usually 
treated for 3 to 7 days, other urinary tract infections 7 to 10 days 
and bacterial gastroenteritis for 5 days. 
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Cautions  
 
Not used in children before puberty.  
 
Patients with history of convulsions (seizures, epilepsy), 
myasthenia gravis and defects in glucose-6-phosphate 
dehydrogenase activity or kidney problems are treated carefully.  
 
Norfloxacin is not recommended in pregnancy.  
 
Excessive sunlight should be avoided. Therapy should be 
discontinued if photosensitivity reactions occur. 
 
Haemolytic reactions have been reported in patients with latent or 
actual defects in glucose-6-phosphate dehydrogenase activities 
that had taken norfloxacin. 
 
When a 200 mg dose was administered to nursing mothers, 
norfloxacin was not detected in human milk. However, because 
the dose studied was low and as many medicines are secreted in 
human milk, caution should be exercised when norfloxacin is 
administered to a nursing woman. 
 
Adverse Effects 
 
• Stomach upset, heartburn, abdominal pain, diarrhoea 
• Headache, dizziness, confusion, convulsions (rare) 
• Skin rash, Increased sensitivity to the sun, Allergy 
• Liver problems, Tendonitis or tendon rupture 
• Vaginal candidiasis (thrush).  
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Pharmacokinetics; 
 
Absorption 
 
Norfloxacin is rapidly absorbed following oral administration. In 
healthy volunteers at least 30 - 40% of an oral dose of norfloxacin 
is absorbed. This results in a serum concentration of 1.5 µg/ml 
being attained approximately one hour after administration of a 
400 mg dose. Mean serum half-life is 3-4 hours and is 
independent of dose. 
 
Following table shows the mean concentrations of norfloxacin in 
various fluids and tissues measured 1 to 4 hours post-dose after 
two 400 mg doses. 
 
Table-A: Mean concentrations of norfloxacin in various fluids 
 
Renal parenchyma 7.3 µg/g 
    Prostate 2.5 µg/g 
    Seminal fluid 2.7 µg/ml 
    Testicle 1.6 µg/g 
    Uterus/cervix 3.0 µg/g 
    Vagina 4.3 µg/g 
    Fallopian Tube 1.9 µg/g 
    Gallbladder tissue 1.8 µg/g 
    Bile 
6.9 µg/ml  
(after two 200 mg doses) 
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Excretion 
 
Renal excretion occurs by both glomerular filtration and net 
tubular secretion, as evidenced by the high rate of renal clearance 
(approx 275 ml/min). After a single 400 mg dose, urinary 
concentrations reach a value of 200 or more µg/ml in healthy 
volunteers and remain above 30 µg/ml for at least 12 hours. In the 
first 24 hours, 33-48% of the medicine is recovered in the urine. 
 
In healthy elderly volunteers (65-75 years of age with normal renal 
function for their age), norfloxacin is eliminated more slowly 
because of their slightly decreased renal function compared to the 
normal population.  
 
Norfloxacin exists in the urine as norfloxacin and six active 
metabolites of lesser antimicrobial potency. The parent compound 
accounts for over 70% of total excretion. The bactericidal potency 
of norfloxacin is not affected by the ph of urine. 
 
The protein binding is less than 15%. Peak serum levels of 
norfloxacin are slightly lower when administered with food than 
fasting. 
 
Norfloxacin is suitable for the treatment of patients with renal 
insufficiency. For these patients the recommended dose is 400 mg 
once daily. At this dosage, concentrations in tissues or body fluids 
exceed the MIC's for most pathogens sensitive to norfloxacin.  
 
Interactions  
 
Multivitamins, iron, zinc, antacids and sucralfate should not be 
taken 2 hours before or 2 hours after using norfloxacin because 
taking them too close to a dose of norfloxacin can greatly 
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decrease the effects of the antibiotic as they may interfere with 
absorption resulting in lower serum and urine levels of norfloxacin. 
 
Antagonism has been demonstrated in vitro between norfloxacin 
and nitrofurantoin. 
 
Elevated plasma levels of theophylline have been reported with 
concomitant quinolone use. Therefore, monitoring of theophylline 
plasma levels should be considered and dosage of theophylline 
adjusted as required. Elevated serum levels of cyclosporin have 
been reported with concomitant use with norfloxacin.  
 
Quinolones, including norfloxacin, may enhance the effects of the 
oral anticoagulant warfarin or its derivatives. When these products 
are administered concomitantly, prothrombin time or other suitable 
coagulation tests should be closely monitored. 
 
Some quinolones, including norfloxacin, have also been shown to 
interfere with the metabolism of caffeine. This may lead to reduce 
clearance of caffeine and a prolongation of its plasma half-life. 
 
Animal data have shown that quinolones in combination with 
fenbufen can lead to convulsions. Therefore, concomitant 
administration of quinolones and fenbufen should be avoided. 
 
Co-administration of probenecid does not affect serum 
concentrations of norfloxacin, but urinary excretion of the 
medicine diminishes. 
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 Review of methods of analysis 
  
Norfloxacin was approved for clinical use in United States in 
November 1986. The drug is available in various formulations 
such as tablets, infusion and ophthalmic solutions for therapeutic 
applications.  
 
Literature survey reveals Titrimetric72-75, UV-visible 
Spectrophotometric 76-78, Fluorimetric79-82 and HPLC methods83-93 
for the determination of the drug in bulk and it’s dosage forms. 
 
Official methods 
 
Bulk powder and tablet of norfloxacin are official in IP72 and 
USP73. Ophthalmic solution of norfloxacin is official in USP74. 
 
The pharmacopoeia72,73 describe UV and IR method for 
identification of the bulk drug and HPLC for formulations.  
 
Indian Pharmacpoeia72 and United States Pharmacopoeia73 
describe non-aqueous titration for estimation of norfloxacin in bulk 
powder. Norfloxacin is dissolved in glacial acetic acid and titrated 
against 0.1 N HClO4. End point is determined potentiometrically. 
 
For identification of norfloxacin USP73 has described UV-
spectrophotometric method. The ultraviolet absorption spectrum of 
1 in 200,000 solution in 0.1 N sodium hydroxide, exhibits maxima 
and minima at the same wavelength as that of a similar 
preparation of USP norfloxacin R.S. concomitantly measured and 
the respective absorptivity calculated on the dried basis, at the 
wavelength of maximum absorbance at about 273 nm, do not 
differ by more than 3.0%. 
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USP73 describes HPLC method for the determination of 
norfloxacin in tablet formulation. The chromatograph equipped 
with C18 column (3.9 mm x 30 cm) and 275 nm UV detectors is 
specified for the purpose. A degassed mixture of phosphoric acid 
solution (1 in 1000) and acetonitrile (850:150) is used as mobile 
phase. Solutions are prepared in the mobile phase. The assay is 
performed at level of 2 µg quantities. 
 
Non-official methods 
 
Boraza et al74 have reported a non aqueous method. Norfloxacin 
has been estimated titrimetrically in glacial acetic acid with 0.1N 
perchloric acid as titrant and quinaldine as an indicator.  
 
Belal et al75 have reported semi-micro titrimetric method for the 
determination of some 4-quinolone derivatives, namely nalidixic 
acid, ofloxacin, norfloxacin and ciprofloxacin hydrochloride. The 
determinations were based on titrating the compounds with either 
sodium hydroxide or tetra butyl ammonium hydroxide or silver 
nitrate. The end points were located conductometrically. The 
method allowed the determination of 1-15 mg of the studied 
compounds. The method was applied to some dosage forms 
containing these compounds. The method was also applied for the 
simultaneous analysis mixture of norfloxacin and trimethoprim in 
their dosage forms.  
 
Rao et al76 have described a spectrophotometric method for the 
estimation of norfloxacin in bulk and its tablets using 3-methyl-2-
benzothiazolinone-hydrazone (MBTH) and cerric ammonium 
sulphate as chromogenic reagents. The chromogen was stable 
only for 30 minutes. Sensitivity of 1 µg/ml of norfloxacin had been 
claimed and Beer’s law was obeyed in the concentration range of 
1-20 µg/ml   of   norfloxacin. 
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Khateeb et al77 have developed two stability indicating 
spectrophotometric methods for the selective determination of 
norfloxacin (NF) in the presence of its decarboxylated degradants. 
The first was based upon measurement of the pH induced 
absorbance difference (∆A) of the drug solution between 0.1 N 
HCl and 0.1 N NaOH at 280 nm. The second involved chelation of 
the intact drug with iron (II) in acetate buffer solution (pH 5.7±0.1). 
A yellow colored chelate was formed absorbing maximum at 358 
nm. The methods were applied for the determination of the intact 
drug both in pure form and in tablet form.  
 
Rakhshanda et al78 have analyzed a total of 49 commercial 
pharmaceutical formulations including ciprofloxacin, norfloxacin, 
ofloxacin, and pefloxacin by UV and colorimetric methods for their 
active ingredient. The results showed that 5 samples contained 
the higher amount as claimed, 3 samples contained the same 
amount while all remaining samples contained the lower amount 
as claimed by the manufacturers. The amount of fluoroquinolone 
varied in the range of +12 to -11%.  
 
Cordoba et al79 have described determination norfloxacin in 
gastric juice in presence of different antacids by fluorescence and 
UV behavior.  
 
Tomas et al80 have reported the fluorimetric methods for 
determination of norfloxacin in pharmaceutical preparations based 
on its reaction with aluminium (III) ion to form a strongly 
fluorescent complex. First-derivative constant wavelength 
synchronous fluorescence spectrometry was used for the 
determination of norfloxacin in the presence of nalidixic acid. The 
determination of norfloxacin in urine without the need of tedious 
pre-separation was achieved by using zero-crossing second-
derivative synchronous fluorescence spectrometry. 
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Cordoba et al81 have developed analytical methods for quality 
control of norfloxacin capsules by modification of fluorescent 
properties of norfloxacin in the presence of certain antacids.  
 
Daz et al82 have studied effect of photo degradation on the 
fluorescent properties of norfloxacin. Norfloxacin is a very thermo 
stable but photosensitive drug; especially in solution leading to the 
formation of an ethylenediamine degradate. The modification of 
the fluorescent properties of norfloxacin in acid solution after 
exposure to fluorescent light and the degradation mechanisms 
were studied by two analytical methods previously developed and 
validated for norfloxacin; ultraviolet spectrophotometry (UV) and 
spectrofluorimetry (FL). Data obtained revealed that there were no 
significant modifications of the UV signal and of the recoveries 
obtained by the method. However, 27% increase of the 
fluorescent signal after light exposure of norfloxacin solutions for 
15 months. Using a previously validated HPLC method for the 
photo stability studies of norfloxacin, a loss of 5% with respect to 
the initial drug amount was observed. The study of UV and 
fluorescence spectra evidenced the formation of the degradation 
product, which induced significant modification of the fluorescent 
properties of norfloxacin samples.  
 
Sane et al83 have described HPLC method for determination of 
norfloxacin in dosage form using nalidixic acid as internal 
standard and microbondapack C18 column (3.9mm x 30cm). 
Mixture of methanol, water and diethyl amine (75:25:0.25) 
adjusted to pH 6.5 with diluted phosphoric acid, was used as 
mobile phase. 
 
Lode et al84 have developed a high performance liquid 
chromatographic method using Lichrasorb FP18 (4.6mm x 25cm) 
as stationary phase and a mixture of equal volumes of borate 
buffer (pH-10) and acetonitrile as mobile phase.  
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Groeneveld et al85 have published high performance liquid 
chromatographic method for determination of ofloxacin, 
ciprofloxacin, norfloxacin and perfloxacin in serum.  
 
Liu et al86 have established a column switching HPLC method for 
the determination of norfloxacin, and active dissociation product of 
silver norfloxacin, in guinea pig plasma and tissues. The pre 
treating column (50 mm x 5 mm ID) and analytical column (150 
mm x 5 mm ID) were packed with mu-Bondapak C18, 37-50 
microns and YWG-C18, 10 microns, respectively. A mixture of 
methanol, 0.008 M phosphate buffer and 0.05 M tetra butyl 
ammonium bromide (25:75:4) was used as the mobile phase with 
a flow rate of 1 ml/min. The pre- treating mobile phase was 0.008 
M phosphate buffer with a flow rate of 3 ml/min. UV detection was 
made at 280 nm. The results were linear within a range of 2 to 128 
µg/ml norfloxacin for plasma. The lowest detection limit was 0.25 
µg/ml for plasma. The mean recovery of the method was 102% 
with relative standard deviation of less than 7%. 
 
Mizuno87has published simultaneous determination of ofloxacin, 
norfloxacin and ciprofloxacin in human hair by HPLC and 
fluorescence detection.  
 
Al-Deeb et al88 has described stability indicating high performance 
liquid chromatographic (HPLC) method for the determination of 
intact norfloxacin in the presence of its photo degradation 
products. The separation was achieved by gradient elution on a 
Micropak-NH2 column (10 microns, 30 cm x 4 mm) using a mobile 
phase containing acetonitrile, tetrabutyl ammonium hydroxide, o-
phosphoric acid and water at a rate of 2 ml/min with UV-detection 
(278 nm) at ambient temperature.  
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Ravi Sankar et al89 have reported simultaneous estimation of 
metronidazole and norfloxacin in formulations by RP-HPLC.  
  
Rodrigo et al90 have investigated norfloxacin pharmacokinetics in 
rat to predict free interstitial levels of the drug. It was determined 
by micro dialysis and using pharmacokinetics parameters derived 
from total plasma data. Norfloxacin free tissue and total plasma 
levels were determined in Wistar rats after administering 5 and 10 
mg/kg I.V. Bolus doses. Plasma and micro dialysis samples were 
analyzed by high-performance liquid chromatography. 
  
Hesham91 has described spectrofluorimetric, atomic absorption 
spectrometric and spectrophotometric determination of some 
fluoroquinolones including norfloxacin.  
  
In the present work two spectrophotometric methods for 
determination of norfloxacin are developed. In first norfloxacin was 
reacted with paraldehyde and the reaction product coupled with 
dichlone to produce colored chromogens where as in second, 
paraldehyde was replaced by crotonaldehyde.  
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3.2 Experimental 
 
3.2.1  Determination of Norfloxacin using Paraldehyde and 
Dichlone (PDM) 
 
3.2.1.1 Apparatus  
 
Double Beam spectrophotometer Shimadzu 1601 model having 
two matched cells with 1 cm light path was used for spectral 
measurements. 
 
Shimadzu Class-VP Chromatograph equipped with model LC-10-
ATVP pump; SPD-M 10Avp, Diode-Array detector; SCL-10 AVP 
System controller, Rheodyne injection valve with a 20 µl loop was 
used for the determination of drug by official method in 
formulations.  
 
Single pan Shimadzu Libror AEG-220, analytical balance was 
used for weighing had a sensitivity of one tenth of milligram. 
 
Ultrasonic bath Expo make having capacity 1.5 liter was used for 
ultrasonication. 
 
Corning volumetric flasks of 10 ml, 25 ml, 50 ml., and 100 ml 
capacity were used in the study. Thermostatically controlled water 
bath was used to control temperature of reaction mixture. 
 
3.2.1.2 Reagents and materials 
 
Norfloxacin (USP), paraldehyde (IP), dichlone (National), glacial 
acetic acid (BDH), acetonitrile (E. Merck), dimethyl sulphoxide 
(DMSO) (SD'S), dioxane (SD'S), and double distilled water were 
used in the study. 
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All the reagents, chemical and solvents used in the investigation 
were of analytical grade. 
 
Formulations of norfloxacin were procured from local market. 
  
 Preparation of dichlone reagent (2.5 % w/v) 
 
An accurately weighed dichlone (625 mg) was dissolved in and 
diluted to 25ml with dimethyl sulphoxide. 
 
 Preparation of Standard solution of norfloxacin 
 
An accurately weighed norfloxacin (50 mg) was dissolved in and 
diluted to 25ml with DMSO. The solution (6.25 ml) was diluted 
further to 50 ml with the same solvent. The final solution contained 
250 µg of norfloxacin per ml of solution. 
 
3.2.1.3 Determination of absorption maxima  
 
Into a 10 ml volumetric flask, dichlone reagent (2.0 ml), 
paraldehyde (0.2 ml) and standard solution of norfloxacin (1.0 ml) 
were pipetted successively. The total volume in the flask was 
adjusted to 4.0 ml with DMSO and mixed. The reaction mixture 
was allowed to stand at 25°C for 45 minutes. Final volume was 
adjusted to the mark with dioxane and absorbance of the colored 
solution was scanned in the range of 750-350 nm against the 
reagent blank.  
 
Maximum absorbance was obtained at 575nm (Fig. 3.1) 
 
3.2.1.4 Lambert- Beer's curve for norfloxacin 
 
Into a series of 10 ml volumetric flasks, dichlone reagent (2.0 ml), 
paraldehyde (0.2 ml) and standard solution of norfloxacin (0.1, 
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0.2, 0.4, 0.6, 0.8 and 1.0 ml) were pipetted successively and 
mixed. The total volume in the flasks adjusted to 4.0 ml with 
DMSO and allowed to stand at 25°C for 45 minutes. The volume 
was adjusted to mark with dioxane. The absorbance of the 
solution was measured at 575 nm against the reagent blank. 
 
The Lambert- Beer’s law was obeyed in the concentration range of 
2.5 to 25 µg of norfloxacin per ml of solution. (Fig.3.2). 
 
3.2.1.5 Factors affecting the development of color 
 
 Effect of concentration of paraldehyde reagents 
 
Into a series of 10 ml volumetric flask, dichlone reagent (2.0 ml), 
different volume of paraldehyde (0.05, 0.1, 0.15, 0.2, 0.4 ml) and 
standard solution of norfloxacin (1.0 ml) were pipetted and mixed. 
The total volumes in the flasks were adjusted to 4.0 ml with DMSO 
and allowed to stand at 25°C for 45 minutes. Final volume was 
adjusted to the mark with dioxane and absorbance measured at 
575 nm against the reagent blank.  
 
The absorbance increased as concentration of the paraldehyde 
was increased. Limiting maximum absorbance was reached with 
0.2 ml paraldehyde reagent, which remained constant on 
increasing the volume of paraldehyde. (Fig. 3.3) 
  
 Effect of concentration of dichlone reagent 
 
Into a series of 10 ml volumetric flask different volume of dichlone 
reagent (0.25, 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 ml), paraldehyde (0.2 
ml) and standard solution of norfloxacin (1.0 ml) pipetted, mixed 
and analyzed as described under section 3.2.1.4.  
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Color intensity of the reaction mixture increased with 
concentration of the dichlone reagent. Maximum absorbance was 
obtained with 2.0 ml dichlone reagent, which remained constant 
on further increasing the volume of dichlone reagent. (Fig. 3.4) 
 
  Effect of temperature 
 
Into series of 10 ml volumetric flask, dichlone reagent (2.0 ml), 
paraldehyde (0.2 ml) and standard solution of norfloxacin (1.0 ml) 
were pipetted successively and mixed. The volume in the flasks 
were adjusted to 4.0 ml with DMSO and maintained at different 
temperature (20, 25, 37, 45, 60°C) for 45 minutes. The flasks 
cooled to room temperature, a volume adjusted to the mark with 
dioxane and absorbance of the solution was measured at 575 nm 
against the reagent blank. 
 
Maximum color intensity was obtained at 25°C, which decreased 
with further increasing the temperature. (Fig. 3.5) 
 
 Time for development of maximum color intensity and color 
stability 
  
Into series of 10 ml volumetric flask, dichlone reagent (2.0 ml), 
paraldehyde (0.2 ml) and standard solution of norfloxacin (1.0 ml) 
were pipetted successively and mixed. The total volume in the 
flasks were adjusted to 4.0 ml with DMSO and allowed to stand at 
25°C for different time interval (5, 15, 30, 45 and 60mins). Final 
volume was adjusted to mark with dioxane and absorbance of 
reaction mixture was measured at 575nm against reagent blank. 
  
The color intensity increased up to 45 minutes and the chromogen 
was observed to be stable for 1 hour   at room temperature 
(Fig.3.6). 
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3.2.1.6 Determination of norfloxacin in bulk powder 
 
Into a series of 25 ml volumetric flasks, different amount of 
accurately weighed norfloxacin (20, 30, 40, 50, 60 mg) was 
dissolved in and diluted to the mark with dimethylsulfoxide. The 
solutions (5.0 ml) were diluted further to 50.0 ml with the same 
solvent. The diluted solutions (1.0 ml) were analyzed as described 
under 3.2.1.4.  
 
Amount of norfloxacin was calculated by referring to the standard 
curve. (Table 7) 
 
 3.2.1.7 Determination of norfloxacin in tablets 
 
Twenty tablets were weighed accurately and powdered. The 
powder equivalent to norfloxacin 50 mg was transferred into a 25 
ml volumetric flask containing glacial acetic acid (1.0 ml) and 
mixed thoroughly. Acetonitrile (20.0 ml) was added and the flask 
sonicated for 30 minutes. Volume was adjusted to mark with 
acetonitrile and filtered through sintered glass funnel G3. 
Rejecting first few ml, the filtrate (5.0 ml) was diluted further to 
50.0 ml with DMSO. The Solution (1.0 ml) was analyzed as 
described under 3.2.1.4. 
 
The amount of norfloxacin was calculated by referring to standard 
curve. (Table 8) 
 
3.2.1.8 Determination of norfloxacin in ophthalmic solution 
 
Norfloxacin ophthalmic solution equivalent to norfloxacin (15mg) 
was pipetted into a 100 ml volumetric flask and volume was 
adjusted to mark with DMSO. The solution (1.0 ml) was analyzed 
as described under 3.2.1.4. The amount of norfloxacin was 
determined by referring to the standard   curve. (Table 8) 
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3.2.2 Determination of Norfloxacin using Crotonaldehyde 
and Dichlone (CDM) 
 
3.2.2.1 Apparatus:  As described in 3.2.1.1 
 
3.2.2.2 Reagents and materials 
 
Norfloxacin (USP), crotonaldehyde (Johnson), dichlone (National), 
glacial acetic acid (BDH), acetonitrile (E. Merck), dimethyl 
sulphoxide (SD'S), and double distilled water were used in the 
study.  
 
All the reagents, chemicals and solvents used in the investigation 
were of analytical grade. 
 
The dosage forms of norfloxacin were procured from local market. 
 
Preparation of dichlone solution (1.5 % w/v) 
 
Dichlone (750 mg) was dissolved in and diluted to 50 ml with 
DMSO. 
 
Preparation of crotonaldehyde solution (20 % v/v) 
  
Crotonaldehyde (10.0 ml) was transferred into 50 volumetric flask 
and diluted to mark with DMSO. 
     
   Preparation of standard solution of norfloxacin  
 
Accurately weighed norfloxacin (50 mg) was transferred into a 25 
ml volumetric flask, containing glacial acetic acid (1.0 ml) and 
dissolved. Volume was adjusted to the mark with acetonitrile. The 
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solution (5 ml) was diluted further to 50 ml with DMSO. The final 
solution contained 200 µg of norfloxacin per ml of solution. 
 
3.2.2.3 Determination of absorption maxima 
 
Into a 10 ml volumetric flask, dichlone solution (1.0 ml), 
crotonaldehyde solution (1.0 ml) and standard solution of 
norfloxacin (1.0 ml) were pipetted successively. The total volume 
was adjusted to 4.0 ml with DMSO, mixed and maintained at 55° 
C in water bath for 15 minutes. The flask cooled to room 
temperature and final volume was adjusted to the mark with 
DMSO. Absorbance of the colored solution was scanned from 
800-400 nm against blank solution prepared in the similar manner 
replacing the drug solution by DMSO.  
 
Maximum absorbance was obtained at 665 nm. (Fig.3.7)  
 
3.2.2.4 Lambert-Beer's curve for norfloxacin 
 
Into a series of 10 ml volumetric flask, dichlone solution (1.0 ml), 
crotonaldehyde solution (1.0 ml) and standard solution of 
norfloxacin (0.1, 0.2, 0.5, 0.75 and 1.0 ml) were pipetted and 
mixed. The total volume in the each flask was adjusted to 4.0 ml 
with DMSO and mixed. The flasks were maintained at 55° C in 
water bath for 15 minutes, cooled to room temperature and 
volume was adjusted to the mark with DMSO. The absorbance of 
the colored solution was measured at 665 nm against the reagent 
blank. 
 
Lambert-Beer’s Law was observed in the concentration the range 
of 2.0 to 20.0 µg of norfloxacin per ml of reaction mixture. 
(Fig.3.8) 
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3.2.2.5 Factors affecting development of maximum color intensity 
 
Effect of concentration of crotonaldehyde reagent  
 
Into a series of 10 ml volumetric flask, dichlone solution (1.0 ml), 
different volume of crotonaldehyde solution (0.25, 0.5, 0.75, 1.0, 
1.25, 1.5 ml) and standard solution of norfloxacin (1.0 ml) were 
pipetted and mixed. The total volume in the each flask were 
adjusted to 4.0 ml with DMSO and analyzed as described under 
3.2.2.4.  
 
Maximum absorbance was obtained in the presence of 1.0 ml 
crotonaldehyde reagent, which remained constant on further 
increasing the volume of the reagent. (Fig. 3.9) 
 
Effect of concentration of dichlone reagent 
 
Into a series of 10 ml volumetric flask, different volume of dichlone 
solution (0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 and 1.5 ml), 
crotonaldehyde solution (1.0 ml) and standard solution of 
norfloxacin (1.0 ml) were pipetted. The total volume in the flasks 
were adjusted to 4.0 ml with DMSO and analyzed as described 
under 3.2.2.4.   
 
Maximum absorbance was obtained with 1.0 ml dichlone reagent, 
which remained constant on further increasing the volume of the 
reagent. (Fig. 3.10) 
 
Effect of temperature 
 
Into a series of 10 ml volumetric flask, dichlone solution (1.0 ml), 
crotonaldehyde solution (1.0 ml) and standard solution of 
norfloxacin (1.0 ml) were pipetted. The total volume in the flask 
was adjusted to 4.0 ml with DMSO and mixed. The flasks were 
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maintained at different temperature (20, 30, 40, 50, 55, 60, 65, 
70°C) in water bath for 15 minutes, cooled and diluted to the mark 
with DMSO and absorbance was measured at 665 nm against the 
reagent blank.  
 
Maximum color intensity was obtained at 55° C, which decreases 
on increasing temperature. (Fig. 3.11) 
 
Time for development of maximum color intensity and color 
stability  
 
Into a series of 10 ml volumetric flask, dichlone solution (1.0 ml), 
crotonaldehyde solution (1.0 ml) and standard solution of 
norfloxacin (1.0 ml) were pipetted and mixed. The total volume in 
the flask was adjusted to 4.0 ml with DMSO and mixed. The flasks 
were maintained at 55° C in water bath for different time interval 
(5,10,15,20,25,30 minutes). The flasks were cooled to room 
temperature and final volume was adjusted to the mark with 
DMSO. The absorbance of colored solution was measured at 665 
nm against the reagent blank.  
 
Maximum color intensity was observed at 15 minutes, which 
decreases slowly. (Fig.3.12) 
 
3.2.2.6 Determination of norfloxacin in bulk powder 
 
Into a series of 25 ml volumetric flasks containing glacial acetic 
acid (1.0 ml), different amount of accurately weighed norfloxacin 
(20, 30, 40, 50, 60) mg was transferred. The drug was dissolved in 
and volume was adjusted to the mark with acetonitrile. The 
solution (5.0 ml) was diluted further to 50ml with DMSO. The 
solution (1.0 ml) was analyzed as described under 3.2.2.4.  
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The amount of norfloxacin was determined by referring to the 
standard curve. (Table 11)  
 
3.2.2.7 Determination of norfloxacin tablets 
 
Twenty tablets were weighed accurately and powdered. The 
powder equivalent to norfloxacin (50 mg) was transferred into a 25 
ml volumetric flask containing glacial acetic acid (1.0 ml) and 
mixed thoroughly. Acetonitrile (20 ml) added and sonicated for 30 
minutes. Volume was adjusted to the mark with acetonitrile and 
filtered through a sintered glass funnel (G3). Rejecting first few 
ml, the filtrate (5 ml) diluted to 50 ml with DMSO. The solution (1.0 
ml) was analyzed as described under 3.2.2.4.  
 
The amount of norfloxacin was determined by referring to the 
standard curve. (Table 12)  
  
3.2.2.8 Determination of norfloxacin in ophthalmic solution 
 
Norfloxacin ophthalmic solution equivalent to norfloxacin (15 mg) 
was pipetted into a 100 ml volumetric flask and volume was 
adjusted to the mark with DMSO. The solution (1.0 ml) was 
analyzed as described under 3.2.2.4.  
 
Amount of norfloxacin was determined by referring to the standard 
curve. (Table 12)  
 
3.2.2.9 Determination of norfloxacin in combination with tinidazole     
tablets  
 
Twenty tablets were weighed accurately and powdered. Weight of 
the powder equivalent to norfloxacin (50 mg) was weighed 
accurately and transferred into a 25 ml volumetric flask containing 
glacial acetic acid (1.0 ml) and mixed thoroughly. Acetonitrile (20 
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ml) was added and sonicated for 30 minutes. Volume was 
adjusted to the mark with acetonitrile and filtered through a 
sintered glass funnel (G3). Rejecting first few ml, the filtrate (5 ml) 
was diluted to 50 ml with DMSO. Solution (1.0 ml) was analyzed 
as described under 3.2.2.4. 
 
The amount of norfloxacin was determined by referring to the 
standard curve. (Table 12)  
 
Validation of the methods 
 
Both the methods (PDM and CDM) were validated in terms of 
linearity, precision and accuracy.  
? Linearity between absorbance and concentration by 
regression analysis. 
? Precisions by performing parallel determinations on intraday 
and interday bases.  
?  Accuracy by recovery study and comparing the results with 
that of official/reported method. 
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3.3    Results   and   Discussion 
 
Norfloxacin contains the secondary amino piperazine moiety at 
the 7-position. It has also been reported that secondary amines 
react with an aldehyde containing active alpha hydrogen to give 
enamines. Enamines are anionic carbon nucleophile and can 
easily displace halogen atom from a halogenated quinone to form 
an extended conjugated chromophore48. Above reaction have 
been exploited in the spectrophotometric determination of 
norfloxacin. 
  
In the present work two spectrophotometric methods for the 
determination of norfloxacin have been developed, first using 
paraldehyde and dichlone reagent (PDM) and the second using 
crotonaldehyde and dichlone reagent (CDM).  
  
Determination of norfloxacin using paraldehyde and 
dichlone reagent (PDM)   
 
It is reported that secondary amines reacts with acetaldehyde in 
presence of dichlone to give purple color compounds. The purple 
compound absorbed maximum at 564 nm in pure dioxane and had 
an absorptivity of 13,30036.  
 
Use of acetaldehyde in presence of dichlone is reported in the 
determination of secondary amino group containing drugs such as 
ephedrine hydrochloride and propranolol 4. 
 
However use of acetaldehyde is inconvenient for routine analysis, 
because acetaldehyde is required to be freshly prepared and also 
it is difficult to handle at room temperature (B.P. 21°C).  
 
There is no evidence of use of paraldehyde as analytical reagent.  
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Since paraldehyde exists in equilibrium with acetaldehyde, 94.3% 
on paraldehyde side at 15 °C, it has been used as source of 
acetaldehyde for synthesis.43 Moreover at room temperature; it is 
a stable liquid (B.P.124.4°C). Therefore exploitation of 
paraldehyde as a source of acetaldehyde in situ, for the 
determination of secondary amino group containing drug could be 
justified. 
 
In the present method, norfloxacin is reacted with paraldehyde in 
the presence of dichlone to produce a purple chromogen. 
 
In the preliminary experiment, the reaction was carried out in 
different solvents; like benzene, methanol, acetonitrile, dioxane, 
DMF and DMSO. Best results were obtained in DMSO. Therefore 
dichlone reagent and standard solution of norfloxacin were 
prepared in DMSO.  
 
When standard solution of norfloxacin, paraldehyde and dichlone 
reagent were added successively and allowed to react, colored 
solution was obtained. But the absorption of colored solution was 
not reproducible. The probable reason thought was instability of 
the enamine, reaction product of norfloxacin and acetaldehyde. 
The enamines get decomposed before coupled to the dichlone. 
The extent of decomposition depends upon time interval between 
addition of paraldehyde and dichlone reagent. This was confirmed 
by varying the time interval between the addition of paraldehyde 
and dichlone reagent. In the experiment absorbance of the 
reaction mixture was observed to decrease as time interval 
between additions of the paraldehyde and dichlone reagent was 
increased.  
 
Maximum and reproducible absorbance was observed when the 
time interval between the addition of paraldehyde and dichlone 
reagent was made zero; means both the reagents were added 
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simultaneously to the solution of norfloxacin or rather when 
norfloxacin solution was added into a mixture of the reagents.  
 
Final volume was adjusted with dioxane because of the aqueous 
media the dichlone reagent precipitate out. Dioxane was also 
found better solvent for the stability of chromogens. 
 
Finally dichlone reagent, paraldehyde and standard solution of 
norfloxacin were added in the order and allowed to react in DMSO 
medium at 25°C, for 45 minute. A stable purple colored 
chromogen was obtained. Final volume of the reaction mixture 
was adjusted with dioxane. The absorbance spectrum of the 
colored solution was scanned from 750 to 350 nm using double 
beam spectrophotometer. Maximum absorption was observed at 
575 nm. (Fig. 3.1) 
 
Lambert - Beer's law was obeyed in the concentration range of 
2.5-25 µg of norfloxacin per ml of reaction mixture. (Fig. 3.2) 
 
Effect of various experimental conditions such as concentration of 
reagents, temperature and time of reaction were optimized, to 
maximize sensitivity, reproducibility and stability of the method.  
 
The intensity of the color product formed, by reaction of 
norfloxacin, paraldehyde and dichlone, was increased as 
concentrations of the reagents were increased. Maximum color 
intensity was observed with 0.2 ml paraldehyde and 2.0 ml of the 
dichlone reagents. On further increasing the concentrations of the 
reagents absorbance remained almost constant. (Fig. 3.3 and 3.4) 
 
The effect of temperature on the development of color product 
was studied. Maximum color intensity was obtained at 25°C and at 
higher temperature color intensity decreases. (Fig. 3.5)  
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When reaction time was varied, the intensity of the colored 
solution continued to increase with time. Maximum color was 
produced at 45 minutes. The color was observed stable for one 
hour. (Fig. 3.6) 
 
Bulk powder and formulations of norfloxacin were analyzed by 
proposed method. The results are comparable to that obtained by 
official methods73. (Table 7, 8)  
 
Proposed mechanism of the reaction 
 
Norfloxacin reacts with acetaldehyde (generated in situ from 
paraldehyde) and forms an unstable hemiaminal, which with the 
loss of water molecule gives a substituted vinylamine92. The vinyl 
amine acts as an anionic carbon nucleophile93 and condenses 
rapidly with dichlone to give purple colored chromogen. 
 
The above mechanism can be justified by following facts. When 
secondary amine, acetaldehyde and dichlone are mixed, there are 
two possible reactions (a) formation of vinylamine by reaction of 
acetaldehyde and the amine and its condensation with dichlone 
(b) formation of alkyl amino naphthoquinone in direct reaction 
between the amine and dichlone. Rate of reaction (a) is very much 
higher than the (b). However formation of the later compound as 
minor product of the reaction has been reported when reaction 
was carried out in nonpolar solvent like benzene, dioxane etc36. 
 
However in the proposed method, the reaction is carried out in an 
aprotic polar solvent DMSO in which, SN2 reactions go as much 
as million times faster than in protic solvent like methanol and 
methanol-water mixture94. Therefore probability of (b) direct 
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reaction between secondary amine (norfloxacin) and dichlone 
becomes negligible.  
Assuming that only reaction (a) occurs, the formation of 
chromogen may be explained on the bases following sequence of 
the reactions. 
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  1-Ethyl-6-fluoro-1, 4-dihydro-4-oxo-7- [4’-vinyl(2”-(8”’- Chloro-2”’ 
  , 7”’-naphthoquinoyl))) piperazinyl]-3-quinolinecarboxylic acid 
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Validation of the proposed method (PDM)  
 
Linearity 
  
Linearity is the ability of the analytical method, within a given 
range to obtain best result that is directly proportional to 
concentration of analytes in the sample. 
 
To find out linearity between absorbance and concentration, 
absorbance of the reaction mixture was measured at various 
concentrations of norfloxacin by proposed method. Beer’s curve 
plotted and regression analysis was performed using Microsoft 
Excel.  
 
Good relationship was observed between absorbance and the 
concentration of norfloxacin in the range of 2.5 to 25 µg/ml of 
reaction mixture. (Fig.  3.2)  
 
The linear equation of norfloxacin obtained was,   
 
   y  = 0.043 x + 0.007   
  
   Where y = Absorbance     
     x = norfloxacin µg / ml. 
 
The correlation coefficient (r2) obtained was 0.9980.  
 
Sensitivity 
 
Sensitivity of analytical method is lowest limit of concentration 
of analyte in the sample that can be quantified with the 
acceptable precision and accuracy under stated experimental 
condition.  
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Sandell's sensitivity (S.S.) of the method is defined, as the 
concentration of analyte that produce 0.001 AU. Using above 
cited regression line (y=0.043 x), S.S. was calculated. The 
propose method has S.S. of 0.02325 µg cm-2 per 0.001-AU.  
 
Moreover S.S. is related to molar absorptivity by equation;  
 
Sandell’s Sensitivity = Molecular weight / Molar absorptivity 
 
Molar absorptivity of chromophore, calculated for the 
chromogens was 13735. 
 
Precision 
 
Precision is measure of reproducibility or repeatability of the 
analytical method. It is expressed in terms of relative standard 
deviation or coefficient of variance (COV). 
 
Relative standard deviation in the estimation of norfloxacin in bulk 
drug, tablets and eye drops were found 0.74, 0.84 and 0.28 % 
respectively. This result is indicative of good precision of the 
method. (Table 7, 8) 
 
For further evaluating the precision of the method, absorbance of 
the color developed by the method was measured at three-
concentration level, five times in a day (intra day) and once a day 
for five days (inter days). The determinations at each level were 
repeated five times. The coefficients of variance (COV) of the 
absorbance in intra day and inter day were compared by F-test. F 
= SA2 / SB2, where SA and SB are standard deviations of two set. 
The calculated F value (2.06) was found less than the table value 
(7.71), at P=0.05 for df = 4 within sample and df=1 between 
sample, thus there was found no significance difference in intra 
and inter day precision of the method. (Table 9) 
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Accuracy 
 
Accuracy of an analytical method is an agreement between the 
true value and mean of the observed value.  
 
Accuracy may be also be revealed by percentage recovery of 
drug. Recovery studies were carried our by adding known amount 
of norfloxacin at three level to pre-analyzed formulations and re-
analyzing it by proposed method. The determinations were 
repeated five times at each level .The mean % recoveries in the 
determination of the norfloxacin from tablets and ophthalmic 
solution were found 99.02% and 99.16% respectively. (Table 10)  
 
None of the usual diluents, excipients and solvents employed in 
the formulation was found to interfere in the determination of 
norfloxacin by proposed method. 
 
Thus, the proposed method (PDM) is sensitive, precise, accurate 
and simple. It can be used for routine analysis of norfloxacin in 
bulk powder and its dosage forms. 
 
Determination of norfloxacin using crotonaldehyde-
dichlone reagents (CDM) 
 
Crotonaldehyde is an aldehyde containing alpha hydrogen. It reacts 
with secondary amines to give enamines, which can be coupled to 
quinones containing halogens to produce chromophore with extended 
conjugation. Buckley et al have reported synthesis of that diethyl 
aminobutadienyl-naphthoquinone a blue compound with more 
extended chromophore using diethyl amine and crotonaldehyde 36. 
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In the present method, norfloxacin is reacted to crotonaldehyde in 
presence of dichlone. A blue colored solution is obtained. DMSO 
was found best solvent for reaction medium. 
 
When norfloxacin, crotonaldehyde and dichlone were added in the 
given order and reacted in dimethyl sulphoxide, a blue colored 
solution was produced. But like PDM here also the absorbance of 
the colored solution was not reproducible and the probable reason 
must be instability of alkyl amino butadiene (enamines) the 
reaction product of norfloxacin and crotonaldehyde. This was 
confirmed by increasing the time interval between the addition of 
crotonaldehyde and dichlone reagent. Absorbance of the reaction 
mixture was observed to decreases as time interval between 
additions of the reagents was increased. Like PDM, in present 
method also maximum as well as reproducible color was produced 
when both the reagents were added simultaneously or rather 
when norfloxacin solution was added into mixture of the reagents.  
 
For adjusting final volume of the reaction mixture, dichlone being 
insoluble in water, various organic solvents were tried. DMSO was 
found better solvent for the stability of color.  
 
Finally when dichlone reagent, crotonaldehyde reagent and 
standard solution of norfloxacin were added successively and 
allowed to react at 55° C, for 15 minutes. Blue colored solution 
was obtained. Volume of the solution was adjusted with DMSO 
and scanned from 850 to 380 nm. Maximum absorbance was at 
665 nm λmax. (Fig. 3.7) 
 
In the proposed method Lambert-Beer’s law was obeyed in the 
concentration range of 2.0-20 µg of norfloxacin per ml of reaction 
mixture. (Fig.3.8) 
 
                                                                                                                        Norfloxacin   
     65                       
Effect of various experimental conditions on the development and 
stability of color was studied.  
 
Effect of concentration of reagent on intensity of color produced 
was studied. The absorbance the color solution increased with the 
concentration of the reagents up to 1.0 ml each of crotonaldehyde 
and dichlone reagents. On further increasing the concentration of 
the reagents absorbance remained constant. (Fig. 3.9, 3.10) 
 
The effect of temperature on the development of color intensity 
was studied. The development color intensity was affected by 
temperature of reaction mixture. Maximum color intensity was 
observed at 55°C, which decreased on further increasing 
temperature. (Fig. 3.11) 
 
When reaction time was varied, the intensity of the colored 
solution continued to increase with the time. Maximum color 
intensity was obtained at 15 minutes and remained stable for 1 
hour. (Fig.3.12) 
 
Bulk powder and formulations of norfloxacin were analyzed by the 
proposed method. Assay results obtained are comparable to 
pharmacopoeial /reported methods73. (Table 11,12)  
 
 
Proposed mechanism of the reaction  
 
Norfloxacin is a secondary amino piperazine group containing 
drug and reacts with crotonaldehyde to form an unstable 
hemiaminal, which with the loss of water molecule gives a 
substituted alkyl amino butadiene (enamines)92. This act as an 
anionic carbon nucleophile93 and condenses with dichlone to give 
a blue colored product having λ max at 665 nm in DMSO. 
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When secondary amine, crotonaldehyde and dichlone are mixed, 
there are two possible reaction (a) formation of enamines by 
reaction of crotonaldehyde and the amine and condensation of the 
enamines with dichlone (b) formation of alkyl amino 
naphthoquinone from direct reaction between the amine and 
dichlone. Reaction (a) is very much faster than the (b). However 
formation of the later compound as minor product of the reaction 
has been reported when reaction was carried out in nonpolar 
solvent like benzene, dioxane etc36. 
 
But the present method the reaction is carried out in an aprotic 
polar solvent DMSO in which, SN2 reactions go as much as million 
times faster than in protic solvent methanol and methanol-water 
mixture. Therefore probability of direct reaction between 
secondary amino group and dichlone becomes negligible94.  
 
This mechanism can be explained, on the bases of the following 
sequence of the reaction.  
 
 
            
N
NH
N
O
COOHF
CH3
  
N
N
R
H
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O N
N
R
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               Crotonaldehyde    Norfloxacin 
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1-Ethyl-6-fluoro-1, 4-dihydro-4-oxo-7 [4’- butadienyl (4”-(8”’- Chloro-2”’, 
 7”’ -naphthoquinoyl))) piperazinyl]-3-quinolinecarboxylic acid  
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Validation of the proposed method (CDM) 
 
Linearity  
 
To find out linearity, absorbance was measured at various 
concentrations of the norfloxacin by the proposed method and 
regression analysis was performed.   
 
The Lambert-Beer’s law was obeyed in the concentration range of 
2.0 to 20 µg / ml of reaction mixture. (Fig.  3.8)  
 
The linear equation of norfloxacin obtained was,  
 
 y  = 0.0479 x - 0.0023   Where y = absorbance 
         x = norfloxacin µg/ml 
  
The correlation coefficient (r2) obtained was 0.9991.  
 
Sensitivity  
 
Using regression line (y=0.0479 x), Sandell's sensitivity (S.S.) 
of the method was calculated 0.0209-µg cm-2 per 0.001-AU. 
Since Sandell’s Sensitivity = Molecular weight / Molar 
absorptivity. Molar absorptivity of chromophore calculated was 
15279. 
 
Precision  
 
Relative standard deviations in the estimation of norfloxacin in 
bulk drug, plain tablets, eye drops and norfloxacin-tinidazole 
combination tablets were observed 0.22, 0.72, 0.17 and 0.86% 
respectively. (Table 11,12) 
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Precision in the estimation of norfloxacin by CDM, on intra day 
and inter day basis was determined. The results of the intra day 
and inter day were compared by F-test. The calculated F value 
(1.40) is found less than the table value (7.71), at P=0.05 for df = 
4 within sample and df=1 between sample, therefore there is no 
significance difference in intra and inter day precision of the 
method. (Table 13)  
 
Accuracy 
 
Accuracy of analysis was also determined by recovery study .The 
percentage recoveries of norfloxacin, in plain tablets, norfloxacin-
tinidazole combination tablets and ophthalmic solution were found 
98.76%, 98.98% and 99.65% respectively. (Table 14)  
 
None of the usual diluents, excipients and solvents employed in 
the formulation was found to interfere in the determination of 
norfloxacin by proposed method. 
 
The proposed method (CDM) is simple, sensitive, precise and 
accurate. The method may be used for estimation of norfloxacin in 
its bulk powder and dosage form. 
 
In comparison, for estimation of norfloxacin, (CDM) is more 
sensitive, precise and accurate than the (PDM). (Table 15) 
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Fig. 3.1 Absorption spectrum of colored product of norfloxacin 
(PDM) 
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Fig. 3.2 Lambert-Beer’s curve of norfloxacin (PDM) 
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Fig. 3.3 Effect of concentration of paraldehyde reagent on color 
intensity (PDM) 
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Fig.3.4 Effect of concentration of dichlone reagent on color 
intensity (PDM) 
 
         
                                                                                                                        Norfloxacin   
     72                       
0.8
0.85
0.9
0.95
1
1.05
20 30 40 50 60 70
Temperature (0C)
A
bo
rb
an
ce
 a
t 5
75
nm
 
 
 Fig. 3.5 Effect of temperature on color intensity (PDM) 
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 Fig. 3.6 Time for development of maximum color intensity 
 And color stability (PDM) 
 
 
 
                                                                                                                        Norfloxacin   
     73                       
Table 7: Estimation of norfloxacin In bulk powder  
By PDM 
 
% Assay by 
 Weight taken 
(mg) Proposed Method 
(PDM) 
USP73 
Method 
20 98.55 99.90 
30 98.70 99.50 
40 99.35 100.0 
50 97.42 99.60 
60 98.90 99.70 
Mean 98.58 99.74 
%  RSD  0.74     0.21 
   
 
 
 
 
Table 8: Estimation of norfloxacin in formulation  
By PDM 
 
% Assay*by  
Formulation 
 
Labeled 
amount 
Proposed 
method 
(PDM) 
USP 73          
method 
Tablets 400 mg 98.14± 0.82 99.20± 0.31 
Ophthalmic 
solution  0.3% w/v  99.21±0.28 99.85 ± 0.17
 
  *Average of five determinations ± SD 
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Table 9: Intra day-inter day precision in the determination 
     Of norfloxacin by PDM 
 
                 
 
 
 
 
 
 
      *Average of five determinations 
 
 
 
Table 10: Percentage recovery of norfloxacin in the 
formulation by PDM 
Formulation 
And label 
claim 
Amount of 
drug in the 
formulation 
(mg) 
Amount of 
pure drug 
added 
(mg) 
Total 
amount of 
drug found 
(mg) 
% Recovery* 
±S.D. 
 
Tablets 
(400 mg)  
 
 
392.56 
 
30.00 
40.00 
50.00 
422.17 
 432.22 
   441.77 
99.10±0.32 
98.70±0.49 
99.26±0.61 
Ophthalmic 
solution 
(0.3% w/v)  
 
29.8  
Mg /10 ml 
 
15.00 
20.00 
25.00 
44.79 
49.63 
54.77 
99.21±0.36 
99.10±0.29 
 99.17±0.39
  
 
      *Average of five determinations ± SD 
 
Precision  
Intra day Inter day 
Concentration 
Of 
 Norfloxacin 
(µg/ml) Absorbance*
±S.D. COV
Absorbance* 
 ±S.D.  COV 
5 0.218±0.008   3.67 0.215±0.007 3.26 
10 0.432±0.014 3.24 0.430±0.016 3.72 
20 0.858±0.026 3.03 0.860±0.023 2.67 
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Fig. 3.7 Absorption spectrum of the colored product of norfloxacin 
(CDM) 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
0 5 10 15 20 25
Concentration of Norfloxacin (ug/ml)
A
bs
or
ba
nc
e 
at
 6
65
nm
 
 
Fig. 3.8 Lambert-Beer’s curve of norfloxacin (CDM) 
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Fig. 3.9 Effect of concentration of crotonaldehyde reagent on 
color intensity (CDM) 
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Fig. 3.10 Effect of concentration of dichlone reagent on color 
intensity   (CDM) 
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 Fig. 3.11 Effect of temperature on color intensity (CDM) 
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Fig. 3.12 Time for development of maximum color intensity and 
color stability (CDM) 
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Table 11: Estimation of norfloxacin in bulk powder 
by CDM 
 
% Assay by 
   Weight taken
(mg) 
 Proposed 
method (CDM) USP 
73 method 
20 98.75 99.90 
30 99.21 99.50 
40 98.90 100.0 
50 99.20 99.60 
60 99.46 99.70 
Mean 99.10          99.74 
% RSD 00.22          00.21 
 
          
 
 
Table 12: Estimation of norfloxacin in formulations by 
CDM 
 
 
% Assay * by  
Formulation
 
Label claim
 
Proposed 
method 
CDM      
USP 73       
method 
 
Tablets 400 mg  
 
98.90± 0.71 
 
99.20±0.31  
Ophthalmic 
solution 
 
0.3% w/v  
99.45 ± 0.17 
 
99.85 ± 0.17 
 
Norfloxacin 
-tinidazole 
tablet 
400mg 
norfloxacin 
600mg 
tinidazole 
98.27±0.85 
 ----- 
 
     * Average of five determinations ± SD 
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Table 13: Intra day-inter day precision in the determination of 
norfloxacin by CDM 
       
Precision  
Intra day Inter day 
Concentration 
of 
norfloxacin 
(µg/ml) Absorbance*
±S.D. COV 
Absorbance* 
 ±S.D.  COV 
5 0.239±0.007 2.93 0.237±0.006 2.53 
10 0.472±0.013 2.75 0.477±0.014 2.94 
20 0.955±0.022 2.30 0.950±0.023 2.42 
 
* Average of five determinations 
 
 
 
 
Table 14: Percentage recovery of norfloxacin in the 
formulation by   CDM     
       
Formulation 
and label 
claim 
Amount of 
drug in the 
formulation 
(mg) 
Amount of 
pure drug 
added 
(mg) 
Total 
Amount of 
drug found 
(mg) 
% Recovery* 
±S.D. 
Tablets 
400 mg 
     
392.56 
 
30.00 
40.00 
50.00 
    422.29 
432.04 
442.19 
98.70±0.57 
99.15±0.66 
98.42±0.71 
Tablet 
norfloxacin 
400mg -
Tinidazole 
600mg  
 
393.08 
 
30.00 
40.00 
50.00 
    422.69 
432.67 
442.71 
98.70±0.32 
98.97±0.49 
99.26±0.61 
Ophthalmic 
solution 
0.3% w/v 
 
29.8 
mg /10 ml 
15.00 
20.00 
25.00 
44.68 
49.62 
54.59 
99.93±0.26 
99.16±0.28 
99.87±0.19 
  
* Average of five determinations ± SD 
 
Table 15: Characteristics of PDM and CDM in determination of 
norfloxacin 
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    Characteristics 
 
 PDM CDM 
 
Wavelength of maximum  
absorbance 
 
        575 nm 665 nm 
 Beer’s law limit (µg /ml) 2.5 to 25 2 to 20 
  Correlation coefficient 
            (r2) 0.9980 0.9991 
  Regression equation    y=0.043 x + 0.007   y=0.0479 x - 0.0023  
  Sandell’s Sensitivity 
  (µg cm-2/0.001 AU) 0.02325 0.0209 
  Molar absorptivity 
   (lit/mole/cm) 13735 15279 
    %  RSD 0.74 0.22 
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4. Spectrophotometric Determination of 
Ciprofloxacin 
 
4.1 Introduction  
 
 
Drug profile: 9,95-97 
 
Chemical name : 1-cyclopropyl-6-fluaro-1, 4 dihydro-4-  
                                        (1-piperazinyl- 3-quinoline carboxylic Acid) 
 
Generic name : Ciprofloxacin 
 
Molecular formula : C17H18FN3O3 
 
Molecular weight : 331. 35 
 
Structural formula : 
     
N
NH
N
O
COOHF
 
 
 
Melting point : 255-257°C 
 
Solubility         : Soluble in acetonitrile, insoluble    in water, 
methanol   and propylene glycol. Their salts 
are soluble in, water, methanol, acetonitrile, 
acetic acid and propylene glycol, insoluble in 
chloroform. 
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Uses 
 
Ciprofloxacin is an antibiotic used to treat certain infections 
caused by bacteria. Ciprofloxacin tablets and suspension are used 
to treat pneumonia; bronchitis; some types of gonorrhea; diarrhea 
caused by bacteria; typhoid fever; and bone, joint, skin, prostate, 
sinus, and urinary tract infections. It is also used to prevent and/or 
treat anthrax in people exposed to anthrax germs in the air. 
Ciprofloxacin is also used with another medication to treat certain 
infections of the internal organs. Ciprofloxacin extended release 
(long-acting) tablets are used to treat urinary tract and kidney 
infections.  
 
Antibacterial spectrum  
 
Ciprofloxacin has in vitro activity against a wide range of Gram-
negativre and Gram-positive microorganisms. The bactericidal 
action of ciprofloxacin results from inhibition of the enzymes 
topoisomerase II (DNA gyrase) and topoisomerase IV, which are 
required for bacterial DNA replication, transcription, repair, and 
recombination. The mechanism of action of fluoroquinolones, 
including ciprofloxacin, is different from that of penicillins, 
cephalosporins, aminoglycosides, macrolides, and tetracyclines; 
therefore, microorganisms resistant to these classes of drugs may 
be susceptible to ciprofloxacin and other quinolones. There is no 
known cross-resistance between ciprofloxacin and other classes 
of antimicrobials. Ciprofloxacin has been shown to be active 
against Bacillus anthracis both in vitro and by use of serum levels 
as a surrogate marker. 
 
Adverse effect 
 
The most common reactions are nausea, abdominal discomfort, 
headache, dizziness, rashes including photosensitive reaction can 
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also occurs. Ciprofloxacin can enhance the action of the 
anticoagulant warfarin and increase the risk of bleeding. 
Ciprofloxacin administered together with theophylline can lead to 
elevated blood levels of theophylline. Though an infrequent 
clinical occurrence, a wide range of animal studies and human 
case reports reveal that use of ciprofloxacin can result in acute 
renal failure, especially when large or excessive doses are taken 
by individuals on chemotherapy or otherwise in a weakened 
condition.  
 
Pharmacokinetics of ciprofloxacin 
 
Absorption  
 
Ciprofloxacin as an oral tablet is rapidly and well absorbed from 
the gastrointestinal tract. The absolute bioavailability is 
approximately 70% with no substantial loss by first pass 
metabolism. Ciprofloxacin maximum serum concentrations are 
shown in the chart for the 250 mg to 1000 mg dose range. 
 
 
Dose (mg) Maximum Serum 
Concentration 
(µg/ml) 
250 1.2 
500 2.4 
750 4.3 
1000 5.4 
 
 
 A maximum serum concentration is attained 1 to 2 hours after oral 
dosing.  
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Distribution 
 
The binding of ciprofloxacin to serum proteins is 20 to 40%, which 
is not likely to be high enough to cause significant protein binding 
interactions with other drugs. 
 
After oral administration, ciprofloxacin is widely distributed 
throughout the body. Tissue concentrations often exceed serum 
concentrations in both men and women, particularly in gential 
tissue including the prostate. Ciprofloxacin is present in active 
form in the saliva, nasal and bronchial secretions, mucus of the 
sinuses, sputum, skin blister fluid, lymph, peritonial fluid, bile, and 
prostatic secretions. Ciprofloxacin has also been detected in lung, 
skin, fat, muscle, cartilage, and bone. The drug diffuses into the 
cerebrospinal fluid (CSF); however, CSF concentrations are 
generally less than 10% of peak serum concentrations. Low levels 
of the drug have been detected in the aqueous and vitreous 
humors of the eye. 
 
Metabolism  
 
Four metabolites have been identified in human urine which 
together account for approximately 15% of an oral dose. The 
metabolites have antimicrobial activity, but are less active than 
unchanged ciprofloxacin. 
 
Excretion  
 
The serum elimination half-life in subjects with normal renal 
function is approximately 4 hours. Approximately 40 to 50% of an 
orally administered dose is excreted in the urine as unchanged 
drug. After a 250 mg oral dose, urine concentrations of 
ciprofloxacin usually exceed 200 µg/ml during the first two hours 
and are approximately 30 µg/ml at 8 to 12 hours after dosing. The 
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urinary excretion of ciprofloxacin is virtually complete within 24 
hours after dosing.  
 
Drug-drug Interactions  
 
When ciprofloxacin tablet is given concomitantly with food, there is 
a delay in the absorption of the drug, resulting in peak 
concentrations that occur closer to 2 hours after dosing rather 
than 1 hour whereas there is no delay observed when 
ciprofloxacin suspension is given with food. The overall absorption 
of ciprofloxacin tablet or suspension, however, is not substantially 
affected. The pharmacokinetic of ciprofloxacin is also not affected 
by food when given in suspension. Concurrent administration of 
antacids containing magnesium hydroxide or aluminum hydroxide 
may reduce the bioavailability of ciprofloxacin by as much as 90%.  
 
Concomitant administration of ciprofloxacin with theophylline 
decreases the clearance of theophylline resulting in elevated 
serum theophylline levels and increased risk of a patient 
developing CNS or other adverse reactions. Ciprofloxacin also 
decreases caffeine clearance by inhibiting the formation of 
paraxanthine after caffeine administration. 
 
Pharmacokinetic studies of the oral (single dose) and intravenous 
(single and multiple dose) forms of ciprofloxacin indicate that 
plasma concentrations of ciprofloxacin are higher in elderly 
subjects (> 65 years) as compared to young adults.  
  
Review of methods of analysis 
 
Official methods  
 
United States Pharmacopoeia98 has described TLC method for 
identification of ciprofloxacin hydrochloride. Stationary phase used 
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is silica gel adsorbent and methylene chloride; methanol; 
ammonia and acetonitrile (4:4:2:1) as mobile phase. 
Chromatogram observed in short and long wavelength ultraviolet 
light. 
 
USP98 method for estimation of ciprofloxacin in bulk, injection and 
tablet form are based on reversed phase HPLC with C18 column 
(4-mm X 25-cm) and 278 nm UV detector. The mobile phase used 
is mixture of 0.0025 M phosphoric acid previously adjusted (with 
triethylamine) to a pH of 3.0± 0.1 and acetonitrile (87:13). The 
determination is carried out at 2.5 micrograms level.  
 
For assay of ophthalmic ointment, USP98 method is HPLC with C18 
column (4.6-cmx25-cm) and 280 UV detector. Mobile phase used 
is solution of 0.005M-tetrabutylammonium phosphate solution 
adjusted to ph of 2.0 with phosphoric acid and methanol 
(750:250). 
 
Indian Pharmacopoeia99 described HPLC method for the assay of 
ciprofloxacin in bulk powder and tablets.  
 
Non-official methods:  
 
Literature survey revealed Spectrophotometry7,100-104 
fluorimetriy105-108 HPLC109-131 biological assay132 FT-Raman 
Spectroscopy133 and capillary electrophoresis134 for the 
determination of ciprofloxacin.  
 
 Rao et al7 have described colorimetric method for estimation of 
ciprofloxacin hydrochloride in tablet using dichlone as reagent. 
Sensitivity of 6 µg/ml was claimed. The method lacks selectivity as 
Ferric gives complexes with phenol, acid and amines. Absorbance 
was measured at 440 nm. 
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Rao et al7 have developed another colorimetric method for 
estimation of ciprofloxacin using, 3-methyl-2-benzothiazolinone 
hydrazone hydrochloride (MBTH), in presence of cerric ammonium 
sulphate. The chromogen produced absorbed maximum at 625 nm 
and was stable for 30 minutes. Beer’s law was obeyed in a very 
narrow range of concentration 6 to 12 µg/ml. 
 
Ciprofloxacin when reacted with ferric chloride a yellow complex 
absorbing maximum at 432 nm was obtained. Beer’s law was 
obeyed from 16-160 µg / ml100. 
 
Suvarna et al101 have reported determination of ciprofloxacin using 
p-benzoquinone as chromogenic reagent. The chromogen had 
absorption maxima at 495 nm. Sensitivity of 10 µg/ml has been 
claimed. 
 
Abdel-Gawad et al102 have published spectrophotometric method 
for the determination of ciprofloxacin in pure form and in tablets 
through charge-transfer complexation reactions.  
 
Survarna et al103 have reported a spectrophotometric method for 
determination of ciprofloxacin, involving phase transfer analysis, 
using bromothymol dye as reagent. 
 
El-Brashy et al104 have developed spectrophotometric methods for 
the determination of ciprofloxacin. In the method ciprofloxacin was 
allowed to react with the bromocresol green in aqueous acidic 
buffer. Highly yellow colored complex was formed after extraction 
into dichloromethane. The complex was quantified 
spectrophotometrically at 412 nm. The proposed method was 
applied to determine these drugs in their tablet formulations. 
 
Sunder Lal et al105 have reported a fluorimetric method for 
estimation of   ciprofloxacin hydrochloride. Ciprofloxacin 
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hydrochloride produces fluorescence at 450 nm in acetate buffer 
(pH 4), when excited with radiation of 280 nm. Sensitivity of 0.5 µg 
per ml has been claimed. 
 
Vega et al106 have published quantitative analysis of 
metronidazole in intravenous admixture with ciprofloxacin by first 
derivative spectrophotometry using the zero-crossing technique of 
measurement. The procedure did not require prior separation 
steps. The method was found to be linear (r2=0.999) in the range 
of 2.5-10 µg/ml for metronidazole in absence or presence of 
ciprofloxacin.  
 
Navalon et al107 have determined the ionization constants of 
ciprofloxacin in solution and in the presence of liposomes by 
fluorimetric titration. 
 
Svetlana et al108 have reported luminescence test method for the 
determination of ciprofloxacin and norfloxacin. The method was 
based on the intramolecular energy transfer from organic acid to 
terbium (Tb3+) ion. Luminescence of terbium (III) complex with the 
drugs adsorbed on the zeolite was studied. Under optimized 
conditions the detection limit was 1µg/ml in urine and human 
plasma. 
 
Claskson et al109 have described HPLC-method with UV detector 
for determination of ciprofloxacin and it’s ethylenediamine 
metabolite in serum and urine. 
 
Groeneveld and Brouwers110 have described quantitative 
determination of ofloxacin, ciprofloxacin, norfloxacin and 
pefloxacin in serum by high-pressure liquid chromatography. The 
quinolones were extracted using dichloromethane under neutral 
conditions, followed by drying under nitrogen and dissolving in 
mobile phase before chromatographic analysis. The stationary 
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phase consisted of a stainless steel column with Nucleosil C18 (4.6 
mm x 25 cm) and of 0.005 M tetrabutyl ammonium iodide solution 
(pH 2.2 adjusted by 0.04 M phosphoric acid) and methanol 
(750:250) were used as mobile phase. UV absorbance was used 
for detection.  
 
Tyczkowskha et   al123   have described HPLC method for 
simultaneous determination of enrofloxacin and it’s primary 
metabolite ciprofloxacin in serum and prostate tissue, at 
concentration limit of 2 µg per ml of ciprofloxacin. 
 
Forlay et al124 have developed high performance liquid 
chromatographic method for the determination of ciprofloxacin in 
influenza vaccine. The stationary phase was a Purospher RP-C18 
column (125 × 3.5 mm; 5 µm); the mobile phase 
acetonitrile/water/phosphoric acid (85%) (15 : 85 : 0.25, v/v/v %), 
was adjusted to pH 3.0 using distilled triethylamine immediately 
before use. Separation was achieved using a flow rate of 0.6 
ml/min at ambient temperature. The ciprofloxacin was detected at 
280 nm. The retention time for ciprofloxacin was 4.60±0.15 min. 
The limit of detection was 2 ng/ml; the limit of quantification was 
found to be 5 ng/ml. 
 
Bai and Tian125 have described RP-HPLC method for 
determination of tinidazole and ciprofloxacin hydrochloride in a 
compound tinidazole soluble powder. The sample was separated 
on a C18 column with a mobile phase of acetonitrile 0.2%TEA (pH  
2.7). The detection wavelength was 296 nm. The calibration curve 
was linear in the range of 2-40 µg/ml for ciprofloxacin 
hydrochloride, r2=0.999. A good linearity was also obtained in the 
concentration range of 2-40 µg/ml r2=0.999 for tinidazole. The 
average recoveries were 100.9%, RSD=1.37% for ciprofloxacin 
hydrochloride and 100.3%, RSD=1.19% for tinidazole respectively.  
 
                                                                                                                                Ciprofloxacin      
  90  
Sunderland et al126 have described a reverse-phase HPLC assay 
for the simultaneous estimation of enrofloxacin and ciprofloxacin 
in pig faeces. Extraction used dichloromethane, 2-propanol and 
0.3 M ortho-phosphoric acid (1:5:4 v/v/v). Separation was 
achieved using a Spherisorb S5 C8 column, heated to 50 °C and a 
mobile phase of 0.16% ortho-phosphoric acid (adjusted to ph 3.0 
with tetrabutylammonium hydroxide solution) with 20 ml 
acetonitrile per liter solution. The method used fluorescence 
detection (λ ex 310 nm; λ em 445 nm), a flow rate of 1 ml/min and 
a 20 µl injection volume. Retention times were approximately 
6 min for ciprofloxacin and 10 min for enrofloxacin. The linearity 
range for both compounds was 0–20 mg/kg, lowest limit of 
quantification 0.3 mg/kg and recoveries were >92%.  
 
Yu-Lin and Chuan have published simultaneous determination of 
trace ofloxacin, ciprofloxacin, and sparfloxacin by micelle TLC–
fluorimetry127. 
 
Vega et al128 have reported Validation of a reversed-phase LC 
method for quantitative analysis of intravenous admixtures of 
ciprofloxacin and metronidazole. 
 
Kevin and Michael130 have developed LC–MS determination of 
fluoroquinolone including ciprofloxacin in beef tissue using the 
Atlantis® dc18 Column (4.6 x150 mm, 5 µm) and fluorescence 
detection:  λ ex 278 nm λ em 445 nm. 
 
Sowinski and Kays131 have reported determination of ciprofloxacin 
concentrations in human serum and urine by HPLC with ultraviolet 
and fluorescence detection. Serum proteins were removed by ultra 
filtration through a filtering device after the addition of a displacing 
reagent. Urine samples were diluted with mobile phase prior to 
injection. Separation was achieved with a C18 reverse-phase 
column and using ultraviolet and fluorescence detection for serum 
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samples and urine samples respectively. The quantitation limits of 
the assay were 20 ng/ml and 100 ng/ml in serum and 1 µg/ml in 
urine. The assay was successfully applied to a pharmacokinetic 
study of ciprofloxacin in healthy volunteers. 
 
Dunett et al132 have detected ciprofloxacin, as a metabolite of 
enrofloxacin in equine hair. This study was aimed to (a) develop 
an analytical method for enrofloxacin and its metabolite 
ciprofloxacin in mane and tail hair, (b) relate measured values to 
doses, routes of administration, hair colour, and (c) demonstrate 
long-term detectability. Samples were extracted in tri-fluoroacetic 
acid at 70 ˚ C. Extracts were cleaned-up by solid-phase extraction 
and analyzed by high-performance liquid chromatography with 
UV-diode array detection. Analyte recoveries were > 87%. Horses 
were sampled after therapeutic enrofloxacin administration either 
orally at 7.5 mg/kg daily for 3-13 days or twice daily for 10-14 
days (Group 1, n=7) or intravenously at 5.0 mg/kg daily for 12 and 
15 days (Group 2, n=2). Enrofloxacin and ciprofloxacin were 
detected at concentrations up to 452 and 19 ng/mg, respectively, 
up to 10 months post-treatment. In vitro, enrofloxacin and 
ciprofloxacin were extensively bound to melanin (> 96%) and in 
vivo, their uptake was 40-fold greater in black than white hair. 
Enrofloxacin and ciprofloxacin concentrations correlated to 
enrofloxacin dose (r2=0.777 and r2=0.769). Enrofloxacin: 
ciprofloxacin ratios were 21:1 and 13:1 following intravenous and 
oral administration, respectively. Longitudinal analyte distributions 
correlated to treatment-sampling interval.  
 
Stavroula et al133 have reported rapid quantitative determination of 
ciprofloxacin in pharmaceuticals using solid-state FT-Raman 
spectroscopy. FT-Raman spectroscopy based on band intensity or 
band area measurements was used for the quantitative 
determination of ciprofloxacin in pharmaceutical solid dosage 
forms. The developed solid-state FT-Raman method does not 
                                                                                                                                Ciprofloxacin      
  92  
require dissolution of solid dosage forms. The method can takes 
just 30 seconds using the analytical readout from a single band.  
 
Katarzyna et al134 have described capillary zone electrophoresis 
for determination of ciprofloxacin and its impurities. 
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4.2 Experimental 
 
  
4.2.1 Determination of Ciprofloxacin using Paraldehyde 
and Dichlone reagent (PDM) 
  
4.2.1.1 Apparatus: As described in chapter 3 
 
4.2.1.2 Reagents and materials 
 
Ciprofloxacin hydrochloride (USP), paraldehyde (IP), dichlone 
(National), glacial acetic acid (BDH), acetonitrile (E. Merck), 
dimethyl sulphoxide (SD’S), dioxane (SD’S) and double distilled 
water were used in the study. All the reagents, chemicals and 
solvents used in the work were of analytical grade. 
 
Formulations of ciprofloxacin were procured from local market. 
 
Preparation of dichlone reagent (2.5 % w/v) 
 
The reagent was prepared as per the procedure described under 
3.2.1.1. 
 
Preparation of standard solution of ciprofloxacin  
 
An accurately weighed ciprofloxacin hydrochloride (50 mg) was 
transferred into a 25 ml volumetric flask containing a mixture of 
glacial acetic acid (1.0 ml) and distilled water (10 ml). The drug 
was dissolved and volume adjusted to the mark with acetonitrile. 
The solution (5.0 ml) was diluted further to 100 ml with DMSO. 
The final solution contained 100 µg of ciprofloxacin hydrochloride 
per ml of solution. 
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4.2.1.3 Determination of absorption maxima 
 
In a 10 ml volumetric flask, dichlone reagent (2.0 ml), paraldehyde 
(0.25 ml), and standard solution of ciprofloxacin (1.0 ml) were 
pipetted successively. The volume in the flask was adjusted to 4.0 
ml with DMSO and mixed. The reaction mixture was maintained at 
30°C for 45 minutes. Final volume was adjusted with dioxane. 
Absorbance of the colored solution was scanned on double beam 
spectrophotometer in the range of 350-700 nm against blank 
solution. The blank solution was prepared similarly in replacing 
the standard solution by an equal volume of dimethyl sulphoxide. 
  
Maximum absorbance was obtained at 575 nm (Fig. 4.1) 
 
 
4.2.1.4 Lambert- Beer’s curve for ciprofloxacin 
 
Into a series of 10 ml volumetric flasks, dichlone reagent (2.0 ml), 
paraldehyde (0. 25 ml) and standard solution of ciprofloxacin 
(0.25, 0.4, 0.6, 0.8 and 1.0 ml) were pipetted successively and 
mixed. The volume in the flasks were adjusted to 4.0 ml with 
DMSO and allowed to stand at 30° C for 45 minutes. The final 
volumes were adjusted to mark with dioxane and absorbance was 
measured at 575 nm against the reagent blank. 
 
The Lambert-Beer’s law was obeyed in the concentration range of 
2.5 to 10 µg of ciprofloxacin hydrochloride per ml of solution. 
(Fig.4.2) 
 
4.2.1.5 Factors affecting development of color 
 
Effect of concentration of paraldehyde reagent 
 
Into a series of 10 ml volumetric flask, dichlone reagent (2.0 ml), 
different volume of paraldehyde (0.05, 0.1, 0.15, 0.20, 0.25, 0.3, 
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0.4 ml) and standard solution of ciprofloxacin (1.0 ml) were 
pipetted successively and mixed. The total volume in the flask was 
adjusted to 4.0 ml with DMSO. The reaction mixtures were 
maintained at 30˚ C for 45 minutes. Final volumes were adjusted 
with dioxane and absorbance of the solutions was measured at 
575 nm against the reagent blank. 
 
Maximum absorbance was obtained in the presence of 0.25 ml 
paraldehyde, which remained constant on further increasing the 
volume of the reagent. (Fig. 4.3) 
 
Effect of concentration of dichlone reagent 
 
Into a series of 10 ml volumetric flasks different volume of 
dichlone reagent (0.5, 1.0, 1.5, 2.0, 2.5, 3.0 ml), paraldehyde 
(0.25 ml) and standard solution of ciprofloxacin (1.0 ml) were 
added successively and analyzed as described under 4.2.1.4.  
 
Maximum absorbance was obtained with 2.0 ml dichlone reagent 
and remained constant up to 3.0 ml of reagent. (Fig.4.4)  
 
Effect of temperature 
 
Into series of 10 ml volumetric flasks, dichlone reagent (2.0 ml), 
paraldehyde (0.25 ml) and standard solution of ciprofloxacin (1.0 
ml) were pipetted successively and mixed. The volume in the 
flasks were adjusted to 4.0 ml with DMSO and maintained at 
different temperature (20, 25, 30, 37, 45, 60°C) for 45 minutes. 
Flasks were cooled to room temperature. Volume was adjusted up 
to mark with dioxane and absorbance of the colored solution was 
measured at 575 nm against the reagent blank. 
 
Maximum color intensity was obtained at 30°C that decreases with 
further increasing the temperature. (Fig. 4.5) 
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Time for development of maximum color and color stability 
  
Into series of 10 ml volumetric flasks, dichlone reagent (2.0 ml), 
paraldehyde (0. 25 ml) and standard solution of ciprofloxacin (1. 0 
ml) were pipetted successively and mixed. The total volume in the 
flasks were adjusted to 4.0 ml with DMSO and maintained at 30°C 
in water bath for different time interval (5, 15, 30, 45, 60 and 120 
mins.). Volume was adjusted to mark with dioxane and 
absorbance measured at 575 nm against reagent blank.  
 
The maximum absorbance was observed after 45 minutes, which 
remained constant for two hours. (Fig.4.6) 
 
4.2.1.6 Determination of ciprofloxacin in bulk powder  
  
 Into a series of 25 ml volumetric flasks containing a mixture of 
glacial acetic acid (1.0 ml) and distilled water (10.0 ml), different 
amount of accurately weighed ciprofloxacin hydrochloride (25, 30, 
45, 55 and 65 mg) was transferred and dissolved. Volume was 
adjusted to mark with acetonitrile. The solution (1.0 ml) diluted 
further to 25 ml with DMSO. The solution (1.0 ml) was analyzed as 
described under 4.2.1.4. 
 
The amount of ciprofloxacin was calculated by referring to the 
standard curve. (Table 16) 
 
4.2.1.7 Determination of ciprofloxacin in tablets 
 
Twenty tablets were weighed accurately and powdered. The 
powder equivalent to ciprofloxacin hydrochloride (50 mg) was 
transferred into a 25 ml volumetric flask, containing glacial acetic 
acid (1.0 ml) and distilled water (10.0 ml). The content was 
sonicated for 30 minutes. Volume was adjusted to the mark with 
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acetonitrile and filtered through sintered glass funnel G3. 
Rejecting first few ml, the filtrate (1.0 ml) was diluted further to 25 
ml with DMSO. The solution (1.0 ml) analyzed as described under 
4.2.1.4. 
 
The amount of ciprofloxacin was calculated by referring to 
standard curve. (Table 17) 
 
4.2.1.8 Determination of ciprofloxacin in ophthalmic solution 
 
Ciprofloxacin ophthalmic solution equivalent to ciprofloxacin 15 
mg was pipetted into a 100 ml volumetric flask and volume was 
adjusted to mark with DMSO. The solution (1.0 ml) was analyzed 
as described under 4.2.1.4.  
 
Amount of ciprofloxacin was found by referring to the standard 
curve. (Table 17)  
 
4.2.2 Determination of Ciprofloxacin using Crotonaldehyde 
and Dichlone reagents (CDM) 
 
4.2.2.1 Apparatus:  As described in 3.2.1.1 
 
 
4.2.2.2 Reagents and materials 
 
Ciprofloxacin hydrochloride (USP), crotonaldehyde (Johnson), 
dichlone (National), glacial acetic acid (BDH), acetonitrile (E. 
Merck), dimethyl sulphoxide (SD'S), and double distilled water 
were used in the study. All the reagents, chemicals and solvents 
used in the work were of analytical grade.  
 
Formulations of ciprofloxacin were procured from local market. 
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Preparation of crotonaldehyde reagent (20 % v/v) and 
dichlone reagent (1.5 % w/v)  
 
These regents were prepared as described under section 3.2.2.2. 
 
Preparation of standard solution of ciprofloxacin  
 
Accurately weighed ciprofloxacin hydrochloride (50 mg) was 
transferred into a 25 ml volumetric flask containing a mixture of 
distilled water (10 ml) and glacial acetic acid (1.0 ml). The drug 
was dissolved and volume adjusted to the mark with acetonitrile. 
The solution (5.0 ml) was diluted further to 50 ml with DMSO. The 
final solution contained 200 µg of ciprofloxacin hydrochloride per 
ml of the solution. 
 
4.2.2.3 Determination of absorption maxima  
 
Into a 10 ml volumetric flask, dichlone reagent solution (1.0 ml), 
crotonaldehyde solution (1.0 ml) and standard solution of 
ciprofloxacin (1.0 ml) were pipetted successively. The total volume 
in the flask was adjusted to 4.0 ml with DMSO and mixed 
thoroughly. The reaction flasks were maintained at 60°C in water 
bath for 15 minutes. The flasks were cooled to room temperature 
and final volume adjusted to mark with DMSO. Absorbance of the 
colored solution was scanned from 800 to 400 nm against the 
blank solution prepared similarly replacing the drug solution by 
DMSO.  
 
Maximum absorbance was obtained at 665 nm. (Fig.4.7)  
 
4.2.2.4 Lambert-Beer’s curve for ciprofloxacin  
 
Into series of 10ml volumetric flasks, dichlone reagent solution 
(1.0 ml), crotonaldehyde solution (1.0 ml) and standard solution of 
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ciprofloxacin (0.1, 0.3, 0.5, 0.75 and 1.0, ml) were pipetted 
successively and mixed thoroughly. The total volume in each flask 
was adjusted to 4.0 ml with DMSO. The flasks were maintained at 
60°C in water bath for 15 minutes and cooled to room 
temperature. The final volume was adjusted to mark with DMSO 
and absorbance was measured at 665 nm against reagent blank. 
 
Beer’s law was obeyed in the concentration the range of 2.0 to 
20.0 µg of ciprofloxacin hydrochloride per ml of reaction mixture. 
(Fig.4.8) 
 
4.2.2.5 Factors affecting development of color 
 
Effect of Concentration of crotonaldehyde reagent  
 
Into a series of 10 ml volumetric flask, dichlone reagent solution 
(1.0 ml), different volume of crotonaldehyde reagent solution 
(0.25, 0.5, 0.75, 1.0, 1.25, 1.5 ml) and standard solution of 
ciprofloxacin (1.0 ml) were pipetted. The total volume in the each 
flask were adjusted to 4.0 ml with DMSO and analyzed as 
described under 4.2.2.4. 
 
Maximum absorbance was obtained in the presence of 1.0 ml 
crotonaldehyde, which remained constant on further increasing 
the volume of the reagent. (Fig. 4.9) 
 
Effect of Concentration of dichlone reagent: 
 
 
Into a series of 10 ml volumetric flask, different volume of dichlone 
solution (0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.5 ml), crotonaldehyde 
solution (1.0 ml) and standard solution of ciprofloxacin (1.0 ml) 
were pipetted successively. The flasks were maintained at 60°C in 
water bath for 15 minutes. The flasks were cooled to room 
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temperature and final volume adjusted to mark with DMSO. 
Absorbance was measured at 665 nm against reagent blank.  
 
Maximum absorbance was obtained with 1.0 ml dichlone reagent, 
which remained constant on further increasing the volume of the 
reagent. (Fig.4.10) 
 
Effect of temperature 
 
Into a series of 10 ml volumetric flask, dichlone solution (1.0 ml), 
crotonaldehyde solution (1.0 ml) and standard solution of 
ciprofloxacin (1.0 ml) were pipetted. The total volume in the flask 
was adjusted to 4.0 ml with DMSO and maintained at different 
temperature (20, 30, 40, 50, 60, 70, 80°C) in water bath for 15 
minutes. The flasks were cooled to room temperature and final 
volume adjusted to mark with DMSO. Absorbance was measured 
at 665 nm against reagent blank. 
 
Maximum absorbance was obtained at 60° C, which decreases on 
further increasing temperature. (Fig. 4.11) 
 
Time for development of maximum color and color stability 
 
Into a series of 10 ml volumetric flask, dichlone solution (1.0 ml), 
crotonaldehyde solution (1.0 ml) and standard solution of 
ciprofloxacin (1.0 ml) were pipetted. The total volume in the flask 
was adjusted to 4.0 ml with DMSO and maintained at 60°C for 
different time interval (5, 10, 15, 20, 30, 45 minutes). The flasks 
were cooled to room temperature and final volume adjusted to 
mark with DMSO and absorbance was measured at 665 nm 
against reagent blank.  
 
Maximum color intensity was obtained at 15 minutes and 
remained constant for 45 minutes. (Fig.4.12) 
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4.2.2.6 Determination of ciprofloxacin in bulk powder  
 
Accurately weighed ciprofloxacin hydrochloride (25,30,35,40,50 
mg) was transferred into 25 ml volumetric flasks, containing a 
mixture of distilled water (10 ml) and glacial acetic acid (1.0 ml). 
The drug was dissolved and volume adjusted to mark with 
acetonitrile. The solution (2.0 ml) was diluted further to 50.0 ml 
with DMSO. The solution (1.0 ml) was analyzed as described 
under 4.2.2.4. 
 
The amount of ciprofloxacin was determined by referring to the 
standard curve. (Table 20)  
 
4.2.2.7 Determination of ciprofloxacin in tablet  
 
Twenty tablets were weighed accurately and powdered. The 
powder equivalent to ciprofloxacin hydrochloride  (50 mg) was 
transferred into a 50 ml volumetric flask containing a mixture of 
distilled water (10.0 ml) and glacial acetic acid (1.0 ml). The flask 
was sonicated for 30 minutes and volume adjusted to the mark 
with acetonitrile. The solution filtered through a sintered glass 
funnel G3. Rejecting first few ml, the filtrate (5.0 ml) was diluted to 
50.0 ml with DMSO. The solution (1.0 ml) analyzed as described 
under 4.2.2.4. 
 
The amount of ciprofloxacin hydrochloride was determined by 
referring to the standard curve. (Table 21)  
  
4.2.2.8 Determination  of ciprofloxacin in ophthalmic solution 
 
Ciprofloxacin hydrochloride equivalent to ciprofloxacin (10mg) was 
pipetted into 10 ml volumetric flask and volume adjusted to mark 
with DMSO. The solution (2.0 ml) was diluted further to 10 ml with 
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DMSO. The solution (1.0 ml) was analyzed as described under 
4.2.2.4.  
 
The amount of ciprofloxacin was determined by referring to the 
standard curve. (Table 21)  
 
4.2.2.9 Determination of ciprofloxacin in combination with tinidazole 
in tablets 
 
Twenty tablets were weighed accurately and powdered. Weight of 
the powder equivalent to ciprofloxacin (50 mg) was transferred 
into a 50 ml volumetric flask containing distilled water (10 ml) and 
glacial acetic acid (1.0 ml) and mixed thoroughly. Acetonitrile (20 
ml) added and sonicated for an hour. Volume adjusted to the mark 
with acetonitrile and filtered through a sintered glass funnel (G3). 
Rejecting first few ml, the filtrate (5 ml) diluted to 25 ml with 
DMSO. The solution (1.0 ml) was analyzed as per the procedure 
described under 4.2.2.4. 
 
The amount of ciprofloxacin was determined by referring to the 
standard curve. (Table 21)  
 
Validation of the methods 
 
Both the methods (PDM and CDM) were validated in terms of 
linearity, precision and accuracy.  
? Linearity between absorbance and concentration by 
Regression analysis. 
?  Precisions by performing parallel determinations on 
intraday and interday bases.  
? Accuracy by recovery study and comparing the results with 
that of official/reported method. 
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4.3  Results   and   Discussion 
 
Like norfloxacin, ciprofloxacin molecule also contain secondary 
amino piperazinyl group. Hence in the present work, reaction 
between the ciprofloxacin and paraldehyde / crotonaldehyde and 
subsequent coupling with dichlone have been used to produce 
color for the development of spectrophotometric methods. 
 
Determination of ciprofloxacin using paraldehyde and 
dichlone (PDM) 
 
Ciprofloxacin is also secondary amino group containing drug. 
Hence it can be reacted to acetaldehyde to form an enamine, 
which if coupled to dichlone forms chromophore with extended 
conjugation. 
 
In the present method (PDM) ciprofloxacin is reacted to 
paraldehyde in presence of dichlone in DMSO. A purple colored 
chromogen is obtained. Paraldehyde is used as a source of 
acetaldehyde. 
 
When ciprofloxacin solution, paraldehyde and dichlone reagent 
were added in the order and allowed to react, the purple colored 
product was obtained but intensity of the color was not 
reproducible for the same reason as discussed in the 
determination of norfloxacin (PDM).  
 
Hence order of addition of reagent was changed. Maximum and 
reproducible absorbance was observed when in dichlone reagent, 
paraldehyde and standard solution of ciprofloxacin were added 
successively.  
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In the preliminary experiments, the reaction was carried out in 
different solvents. Better results were obtained in DMSO.  
 
Various organic solvents were tried for adjusting the final volume 
of reaction mixture. When final volume of reaction mixture was 
adjusted with water precipitation was observed. Among the 
various organic solvents dioxane was found better solvent for the 
stability of chromogen.  
 
Finally dichlone reagent, paraldehyde and standard solution of 
ciprofloxacin were added successively and allowed to react in 
DMSO, at 30°C, for 45 minutes, the purple colored solution was 
obtained having maximum absorption at 575 nm. (Fig. 4.1) 
 
Beer's law is obeyed in the concentration range of 2.0-10 µg of 
ciprofloxacin hydrochloride per ml of reaction mixture. (Fig. 4.2) 
 
Effect of various experimental conditions on development of color 
was studied.  
 
The absorbance at 575 nm of the colored solution obtained by 
reaction of ciprofloxacin, dichlone and paraldehyde was found to 
increase as concentration of paraldehyde and dichlone reagents 
were increased up to 0.25 ml paraldehyde and 2.0 ml dichlone 
reagents. On further increasing the reagent absorbance remained 
constant. (Fig. 4.3, 4.4) 
 
When reaction mixtures of paraldehyde, dichlone reagent and 
ciprofloxacin solution, were kept at different temperature, 
maximum color intensity was observed at 30°C, which decreased 
on further increasing the temperature. (Fig.4.5) 
 
When reaction mixture was allowed to react at 30°C, the color 
intensity continued to increase and maximum color was obtained 
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at 45 minutes, which was observed to be stable for 2 hours. 
(Fig.4.6)  
 
Bulk powder of ciprofloxacin and its formulations were analyzed 
by proposed method. The results obtained are comparable with 
that of pharmacopoeial method98. (Table 16, 17) 
 
Proposed reaction mechanism 
 
Ciprofloxacin is a secondary amino piperazine group-containing 
drug.  When it is reacted with acetaldehyde (generated in situ 
from paraldehyde) forms an unstable hemiaminal. This with loss of 
water molecule gives a substituted vinylamine93. The Vinyl amine 
acts as an anionic carbon nucleophile94 and condenses rapidly 
with dichlone to give purple chromogen. Sequence of the reaction 
involved may be summarized as follow. 
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1- Cyclopropyl -6-fluoro-1, 4-dihydro-4-oxo-7- [1’-(4’-vinyl(2”-(8”’- Chloro-7”’, 
2”’-naphthoquinoyl))) piperazinyl]-3-quinolinecarboxylic acid  
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Validation of the method (PDM) 
 
Linearity  
 
For finding the linearity of the proposed method absorbance of the 
reaction mixture was measured at various concentrations, Beer’s 
curve plotted and regression analysis was performed.  
 
In the present method good linearity was observed between 
absorbance and the concentration of ciprofloxacin in the range of 
2.0 to 10 µg/ml of reaction mixture. (Fig.  4.2) 
 
The linear equation of ciprofloxacin obtained was,   
  
 y  = 0.0341x + 0.0036    
    Where y = absorbance 
                           x = ciprofloxacin hydrochloride µg/ml 
                                 
The correlation coefficient (r2) obtained was 0.9996.  
 
Sensitivity  
 
Using regression line (y=0.0431 x) of Beer’s curve, Sandell's 
sensitivity (S.S.) was calculated 0.0293 µg cm-2 per 0.001-AU 
and molar absorptivity of chromophore produced was 12553. 
 
Precision 
 
Relative standard deviation in the estimation of ciprofloxacin in 
bulk drug, tablet and eye drops are found 0.86, 1.16 and 0.39 % 
respectively. (Table 16, 17) 
 
For further evaluation of precision of the method, determinations 
of the drug in bulk powder were carried out on intra day and inter 
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day basis. The results of the two sets are compared by F-test. The 
calculated F value (1.22) is found less than the table value (7.71), 
at P=0.05 for df = 4 within sample and df=1 between sample, 
hence there is no significance difference in intra and inter day 
precision of the method. (Table 18) 
 
Accuracy 
 
Accuracy of analysis was determined by recovery study in which 
known amount of the standard drug was added to pre-analyzed 
formulations and mixture were re-analyzed by the proposed 
method. The % recoveries in the determination of the ciprofloxacin 
in tablets and ophthalmic solution were found 98.65% and 98.84% 
respectively. (Table 19) 
 
None of the usual diluents, excipients and solvents employed in 
the formulation interfered in the determination of ciprofloxacin by 
proposed method. 
 
The present method (PDM) is accurate, reproducible, sensitive 
and simple and may be used for estimation of ciprofloxacin in bulk 
powder and dosage form.  
 
Determinations of ciprofloxacin using crotonaldehyde 
and dichlone (CDM) 
 
In this method ciprofloxacin is reacted with   crotonaldehyde and 
dichlone in dimethyl sulphoxide. Blue colored solution is obtained. 
 
However when standard solutions of ciprofloxacin, crotonaldehyde 
and dichlone reagent were added in the given order, the color 
produced was not reproducible. The Probable reason thought was 
instability of presumed intermediate alkyl amino butadiene 
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(enamines), the reaction product of ciprofloxacin and 
crotonaldehyde, which decomposes to variable extent before it is 
coupled to dichlone. Hence order of addition of reagent was 
changed.  
 
Maximum and reproducible color was observed when the dichlone 
reagent, crotonaldehyde reagent and standard solution of 
ciprofloxacin were added successively. 
 
For adjusting final volume of reaction mixture, among the various 
solvents tried, DMSO was found best solvent for the stability of 
chromogen. DMSO being aprotic solvent hydrolysis of chromogen 
is not favored. More over being insoluble in water, dichlone 
precipitate out if volume adjusted with water. 
 
Finally dichlone reagent, crotonaldehyde reagent and standard 
solution of ciprofloxacin were added successively and allowed to 
react at 60° C, for 45 minutes. Blue colored solution obtained was 
scanned for absorbance from 850 to 380 nm. The maximum 
absorbance was observed at 665 nm. (Fig. 4.7) 
 
Beer’s law is obeyed in the concentration range of 2.0-20 µg/ml of 
ciprofloxacin hydrochloride. (Fig. 4.8) 
 
Effects of concentration of reagents, temperature and reaction 
time on development color and stability of chromogen were 
studied. 
 
The absorbance of the colored product formed in the reaction of 
ciprofloxacin, crotonaldehyde and dichlone reagents was 
increased with concentration of the reagent; up to 1.0 ml of 
crotonaldehyde solution and 1.0 ml dichlone solution. On further 
increasing the concentration of the reagents absorbance remained 
constant. (Fig. 4.9, 4.10) 
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Effect of temperature on development of color was studied. 
Optimum temperature for the reaction was found 60°C. (Fig. 4.11) 
 
Color intensity of reaction mixture continued to increase up to 15 
minutes. The color was observed stable for 45 minutes at room 
temperature. (Fig. 4.12) 
 
Ciprofloxacin in bulk powder, tablets, ciprofloxacin-tinidazole 
tablets and eye drops of ciprofloxacin were analyzed by proposed 
method (CDM). The results obtained are comparable with 
pharmacopoeial method98. (Table 20, 21) 
 
None of the usual diluents, excipients and solvents employed in 
the formulation interfered in the determination of ciprofloxacin by 
proposed method. 
 
Proposed reaction mechanism 
 
Ciprofloxacin is a secondary amino piperazine group containing 
drug. It reacted with crotonaldehyde in the presence of dichlone in 
DMSO to give blue colored solution having λmax 665 nm.  
 
When secondary amine, crotonaldehyde and dichlone are mixed, 
there are two possible reaction (a) formation of enamines by 
reaction of crotonaldehyde and the amine and its condensation 
with dichlone (b) formation of alkyl amino naphthoquinone from 
direct reaction between the amine and dichlone. Reaction (a) is 
very much faster than the (b). However formation of the later 
compound as minor product of the reaction has been reported 
when reaction was carried out in nonpolar solvent like benzene, 
dioxane etc36.  
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In the present method the reaction is carried out in an aprotic 
polar solvent DMSO in which, SN2 reactions go as much as million 
times faster than in protic solvents methanol and methanol-water 
mixture. Therefore probability of direct reaction between 
secondary amine and dichlone becomes negligible92. 
Therefore when ciprofloxacin is added to the mixture of dichlone 
and crotonaldehyde, through the reaction (a), formation of   blue 
chromogen can be explained as shown by following reactions.  
 
 
N
N
R
H
=Ciprofloxacin=
N
NH
N
O
COOHF
             
    
 
 
CH3
O N
N
R
H
 
 
 Crotonaldehyde  Ciprofloxacin 
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1-Cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7 [1’-(4’- butadienyl (2”-(8”’- Chloro-
7”’, 2”’-naphthoquinoyl))) piperazinyl]-3-quinolinecarboxylic acid  
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Validation of the method (CDM) 
 
Linearity  
 
To find out linearity, absorbance of color produced, at various 
concentrations was measured. Regression analysis of the data 
was done using Microsoft Excel. 
 
The linear equation of ciprofloxacin obtained was  
   
 y= 0.0438x - 0.003   
                        
Where, y = absorbance       
         x = ciprofloxacin hydrochloride µg per ml 
 
The correlation coefficient (r2 = 0.9983) shows good relationship 
between absorbance and the concentration of ciprofloxacin 
hydrochloride in the range of 2.0 to 20.0 µg per ml of reaction 
mixture. (Fig.4.8) 
 
Sensitivity  
 
Using regression equation  y  = 0.0438 x, Sandell’s sensitivity of 
the proposed method calculated was 0.0228 µg cm-2 / 0.001 AU 
and molar absorptivity of the chromophore produced was 16133. 
 
Precision  
 
Relative standard deviations, in the estimation of ciprofloxacin in 
bulk drug, tablets, ophthalmic solution and ciprofloxacin-tinidazole 
combination tablets, were 0.34, 0.83, 0.22 and 0.97 % 
respectively. (Table20, 21) 
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For further evaluation of precision of the method, assay of the bulk 
powder was also carried out on intra day and inter day basis. The 
coefficient of variance of the absorbances of the two sets was 
compared by F-test. The calculated F value (1.53) is less than the 
table value (7.71), at P=0.05 for df = 4 within sample and df=1 
between sample, hence there is no significance difference in intra 
day and inter day precision of the method. (Table 22) 
  
Accuracy 
 
Accuracy of analysis was determined by recovery study in which 
known amount of the standard drug was added to pre-analyzed 
formulations and mixture were re-analyzed by the proposed 
method. The % recoveries obtained in tablets, ciprofloxacin-
tinidazole tablets and ophthalmic solution were 99.08%, 98.94% 
and 99.21% respectively. (Table 23) 
 
None of the usual diluents and excipients observed to interfere in 
the determination. Thus the determination of norfloxacin by CDM, 
this method is selective to secondary amines (ciprofloxacin). 
 
The present method (CDM) is accurate, reproducible, sensitive 
and simple and may be used for routine estimation of ciprofloxacin 
in bulk powder and formulations. 
 
The characteristics of the two methods PDM and CDM for the 
determination of ciprofloxacin are summarized. (Table 24) 
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 Fig. 4.1 Absorption spectrum of colored product of ciprofloxacin 
                                                  (PDM) 
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  Fig. 4.2 Lambert - Beer’s curve of ciprofloxacin (PDM) 
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 Fig. 4.3 Effect of concentration of paraldehyde reagent on color 
intensity (PDM) 
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             Fig. 4.4 Effect of concentration of dichlone reagent on color  
       intensity (PDM) 
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              Fig. 4.5 Effect of temperature on color intensity (PDM) 
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              Fig. 4.6 Time for development of maximum color intensity and 
        Color stability (PDM) 
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Table 16:Estimation of ciprofloxacin in bulk powder  
By PDM 
 
% Assay by Weight taken 
 
(mg) 
 
Proposed method 
(PDM) USP
 method98 
25 98.45 99.28 
30 99.30 99.12 
45 98.35 99.87 
55 97.42 99.54 
65 97.20 99.70 
Average 98.14 99.50 
% RSD 0.86 0.27 
  
  
 
 
 
Table 17: Estimation of ciprofloxacin in formulation by  
        PDM 
 
% Assay* by  
Formulation
 
Labeled 
Value  
 
Proposed method 
(PDM) 
 USP98 method 
 
Tablets 500 mg 97.62 ± 1.13 99.4 0± 0.46 
Ophthalmic 
Solution  
0.3% w/v      98.21±0.38 
 
 
99.45 ± 0.24 
 
 
* Average of five determinations ± SD 
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Table 18: Intra day-inter day precision in the determination of 
      Ciprofloxacin by PDM 
 
Precision  
Intra day Inter day 
Concentration 
of 
ciprofloxacin 
hydrochloride 
(µg/ml) 
Absorbance*
±S.D. COV 
Absorbance* 
 ±S.D. COV 
3 0.101±0.007 6.93 0.099±0.006 6.06 
6 0.198±0.013 6.56 0.201±0.011 5.47 
9 0.304±0.019 6.25 0.303±0.017 5.61 
 
 *Average of five determinations 
 
Table 19: Percentage recovery of ciprofloxacin in the formulation 
 By PDM  
 
Formulation 
and 
Labe claim  
Amount of 
drug in the 
formulation 
(mg) 
Amount of 
pure drug 
added  
(mg) 
Total 
amount of 
drug found 
(mg) 
% Recovery* 
±S.D. 
Tablets 
500 mg 
 
 488.1  
 
20.00 
30.00 
40.00 
507.73 
517.70 
 527.77 
98.13±0.31 
98.65±0.29 
99.17±0.22 
Ophthalmic 
solution 
0.3% w/v  
 
29.5  
mg / 10 ml 
 
15.00 
20.00 
25.00 
   44.31 
49.28 
54.21 
98.77±0.21 
98.89±0.32 
 98.85±0.28 
 
 *Average of five determinations 
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   Fig. 4.7 Absorption spectrum of colored product of ciprofloxacin 
                                        (CDM) 
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     Fig. 4.8 Lambert -Beer’s curve of ciprofloxacin (CDM) 
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Fig. 4.9 Effect of concentration of crotonaldehyde reagent on  
    color Intensity (CDM) 
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  Fig. 4.10 Effect of concentration of dichlone reagent on color 
       intensity (CDM) 
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             Fig. 4.11 Effect of temperature on color intensity (CDM) 
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  Fig. 4.12 Time for development of maximum color intensity and 
       Color stability (CDM) 
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Table 20: Estimation of ciprofloxacin in bulk powder by 
               CDM 
            % Assay by 
 
Weight taken 
 
(mg) 
 
Proposed 
Method CDM
USP 98 
Method 
25 99.25 99.28 
30 99.21 99.12 
35 98.70 99.87 
40 99.12 99.54 
50 99.66 99.70 
Average 99.19 99.50 
% RSD 00.34 00.27 
 
 
 
 
Table 21: Estimation of ciprofloxacin in formulation by 
                            CDM 
% Assay* by 
Formulation Labeled value  
 
Proposed 
Method CDM
 
 
Official/Reported 
Method 
 
Tablets 500 mg  
 
99.05± 0.83
 
 
99.62±0.5198 
 
Ophthalmic 
solution 
0.3% w/v  99.25± 0.22
 
 
99.56±0.1998 
 
 
Ciprofloxacin-
tinidazole 
tablets 
500mgs  
 
99.17±0.97
 
99.02±1.37125 
 
  * Average of five determinations ± SD 
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Table 22: Intra day-inter day precision in the determination of 
ciprofloxacin by CDM 
                     
 
Precision  
Intra day Inter day 
Concentration 
of 
ciprofloxacin 
hydrochloride
(µg/ml) 
Absorbance* 
±S.D. COV 
Absorbance* 
 ±S.D. COV 
5 0.216±0.006 2.28 0.215±0.005 2.32 
10 0.435±0.011 2.53 0.437±0.009 2.06 
20 0.873±0.018 2.06 0.874±0.017 1.95 
 
 *Average of five determinations 
           
 Table 23: Percentage recovery of ciprofloxacin in the  
                           Formulation by CDM  
                  
Formulation 
and label 
claim 
Amount of 
drug in the 
formulation 
(mg) 
Amount of 
pure drug 
added  
(mg) 
Total amount 
of drug 
found 
(mg) 
% 
Recovery* 
±S.D. 
 
Tablets 
500 mg  
 
495.3  
20.00 
30.00 
40.00 
 515.09 
  525.05 
  534.94 
98.97±0.22
99.17±0.28
99.11±0.19
Tablet 
ciprofloxacin 
500mgs -
Tinidazole 
600mgs  
 
495.9  
20.00 
30.00 
40.00 
 515.65 
  525.64 
535.47 
98.77±0.31
99.12±0.13
98.92±0.19
Ophthalmic 
solution  
0.3%w/v 
 
29.8 
 mg/10 ml 
10.00 
15.00 
20.00 
     29.80 
44.69 
49.65 
 99.15±0.18
 99.24±0.15
99.23±0.21
 
*Average of five determinations  
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Table 24: Characteristics of PDM and CDM for determination of 
ciprofloxacin 
                  
 
Characteristics               PDM           CDM 
 
Wavelength of 
maximum absorbance
 
575 nm 665 nm 
Beer’s law limit 
       (µg/ml) 2 to 10 2 to 20 
 Correlation  
 coefficient (r2) 0.9996 0.9983 
 Regression equation    y=0.0341 x + 0.0036   y=0.0438x - 0.003  
Sandell’s Sensitivity
(µg cm-2/0.001 AU) 0.0293 0.0228 
Molar absorptivity 12553 16132 
% RSD  0.85 0.34 
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5. Spectrophotometric Determination of 
Sparfloxacin 
 
5.1  Introduction  
 
Organic compounds containing the amino group have been known 
since early nineteenth century. Thousands of new nitrogenous 
organic compounds of considerable industrial and physiological 
importance have been synthesized. Alkaloids, sulphonamides, 
antihistamine, local anesthetic, antimalarial, antibacterial, 
tranquilizers, hypotensives, narcotics etc. belongs to this class. 
 
Sparfloxacin is the third generation fluoroquinolone antibacterial. 
Due to its intensive and efficient antibacterial activity it is widely 
used in clinical practice. Sparfloxacin contain primary aromatic 
amino group. In the present work, a spectrophotometric method 
based on coupling of diazotized sparfloxacin with Bratton-Marshal 
reagent in hydro alcoholic medium is described. 
 
Drug profile 135,136 
 
IUPAC name               :5-Amino-1-cyclopropyl-7- (cis-3, 5- dimethyl- 
1-piperazinyl)-6,8-difluoro-1,4-dihydro 
  -4- oxo- 3-uinolinecarboxylic   acid. 
 
Molecular formula       :C19H22F2N4O3 
 
CAS No.         :111542-93-9 
   
Molecular weight       :392.41 
 
Melting point:       :266-269 ˚C 
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Dissociation constant  :pka1 = 6.25, pka2 = 9.3 
 
Appearance                :It is yellow color powder 
 
Structure 
 
N
NH
N
O
COOHF
CH3
CH3
NH2
F
 
 
Solubility                   :Soluble in methanol, dimethylsulfoxide 
                                            and acetic acid, insoluble in water  
 
Dosage form             :Tablets, Injections, Eye drops 
 
Clinical applications  
 
Uncomplicated urinary tract infections, complicated urinary tract 
Infections, pyelonephritis, sexually transmitted diseases, 
prostatitis, skin and tissue infections, urethral and cervical 
gonococcal infections, acute exacerbations of chronic bronchitis 
and community-acquired pneumonia. 
 
Structure activity relationship137 
 
Sparfloxacin has an amino group at C-5 position of the quinoline 
ring and thus, differs from other quinolones. Two fluorine atom 
substitutions at C-6 and C-8 positions, combined with the 1-(3,5-
dimethyl) piperazinyl ring substitution at position C-7, increase 
the potency and extend the spectrum of antimicrobial activity. 
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The C-5 amino group confers enhanced in vitro activity against 
Gram-positive bacteria. The cyclopropyl group at position 1 and 
fluorine atom at position 6 in quinoline ring provide activity against 
Gram-negative bacteria. The 3,5 dimethyl groups on piperazinyl 
side chain reduce potential for binding with GABA receptors and 
metabolizing enzymes in liver.  
 
Pharmacokinetics of sparfloxacin138-140 
 
Absorption  
 
Sparfloxacin is well absorbed from the duodenum, jejunum, ileum 
and colon, but not from the stomach. The systemic availability of 
oral sparfloxacin is reported approximately 60% of the dose in rats 
and 80-90% in dogs and monkeys.  
 
Among quinolones now available, sparfloxacin has the longest 
time for which plasma concentration exceeds the minimum 
inhibitory concentrations for 50 or 90% of strains (MIC50, MIC90) 
for representative strains of clinically isolated bacteria. 
 
The effect of food on pharmacokinetics of sparfloxacin has been 
evaluated. Plasma concentration of sparfloxacin administered 
after or during a standard breakfast were equal to or tended to be 
higher (without statistically significant differences) than those 
administered in a fasting state. The tmax, area under the plasma 
concentration-time curve (AUC) and apparent plasma elimination 
half-life (tl/2) were also unaffected by food - it is therefore 
concluded that food intake does not alter the absorption and 
pharmacokinetics of sparfloxacin. 
 
Pharmacokinetic parameters of sparfloxacin are also determined 
after multiple oral doses. The observed plasma concentration of 
sparfloxacin fit well to the predicted curve calculated from the 
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concentration-time profile after the first dose, suggesting that 
multiple doses do not alter sparfloxacin pharmacokinetics. 
 
Distribution 
 
Sparfloxacin was found 37% bound to plasma proteins, in healthy 
volunteers after a single oral dose of 400 mg. The degree of 
binding did not appear to be affected by multiple doses of 
sparfloxacin 200 mg twice daily. Protein binding of sparfloxacin in 
vitro was reported to be 46%, with albumin representing the major 
binding site. 
 
Sparfloxacin is widely distributed in the body tissues and fluids. 
The apparent volume of distribution of sparfloxacin was found to 
be approximately 4.5 L/Kg after oral administration to healthy 
volunteers. As compared to sparfloxacin, other fluoroquinolones 
have smaller volume of distribution, ofloxacin, (1.3L/Kg), 
ciprofloxacin, (1.7 L/Kg). 
 
As expected of a drug with a large Vd value, sparfloxacin 
distributes or penetrates well into many tissues and secretions 
such as sputum, pleural fluid, skin, prostate, gynecological 
tissues, breast milk, otolaryngological tissues and exodontia 
wounds. 
 
It has been reported that sparfloxacin is secreted in a 
considerable amount into saliva and tears. The saliva 
concentrations were 66 to 70% of corresponding plasma 
concentration suggesting that saliva may be a useful specimen for 
the therapeutic drug monitoring of sparfloxacin. 
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Metabolism 
 
The metabolic transformation of sparfloxacin occurs at the 
carboxylic acid group at C-3 position to form a glucoronic acid 
conjugate of the ester type. No other metabolite has been 
detected. 
 
The glucuronide was detected in plasma, urine and bile together 
with unchanged drug, but not in feceas because of hydrolysis of 
glucuronide conjugation in alkaline media and by intestinal flora. 
 
Elimination 
 
Sparfloxacin has a prolonged plasma elimination half-life with 
mean values generally between 18 to 19 hours in single dose 
studies. Sparfloxacin is eliminated mainly via non-renal route. 
About 60% of the drug is excreted in feces and about 40% in 
urine. Urine clearance of unchanged drug accounted for 9-10% of 
dose administered and that of its glucuronide conjugate for 27-
38% of the dose. The biliary excretion of sparfloxacin and its 
conjugate accounted for 1.5 and 11% of the dose administered 
respectively. 
 
It has been reported that the pharmacokinetics parameters, with 
repeated daily doses of sparfloxacin 100 to 400 mg, preceded by 
a loading dose twice, were found to be consistent to that of single 
dose data. Steady-state plasma concentrations were obtained 
more quickly after a loading dose and there was no evidence of 
drug accumulation. 
 
 
 
 
                                                                                                                          Sparfloxacin        
    131
Pharmacokinetics in patients with renal dysfunction 
 
The renal clearance and urinary excretion of sparfloxacin 400 mg 
were found to be significantly lower in patients with moderate 
renal dysfunction (creatinine clearance 10-30 ml/min) and severe 
renal dysfunction (creatinine clearance less than 10 ml/min) as 
compared to healthy control group. The t1/2 was significantly 
higher in patients with renal dysfunction All pharmacokinetics 
parameters except tmax were found to be significantly higher. It 
appears that sparfloxacin elimination is affected and dosage 
modification may be necessary in patients with renal impairment 
where creatinine clearance is less than 30 ml/min. 
   
Drug interactions141 
  
(I) Theophylline 
 
Theophylline pharmacokinetics is well known to other 
fluoroquinolones. Effects of sparfloxacin on the pharmacokinetics 
of theophylline have been investigated in healthy volunteers and 
in six asthmatic patients receiving long-term theophylline therapy. 
There were no statistically significant differences observed in the 
plasma concentration-time profile and pharmacokinetics 
parameters of theophylline between theophylline alone and 
theophylline with sparfloxacin. Urinary excretion of theophylline 
and its metabolite were also not affected by co-administration of 
sparfloxacin. No adverse effects related to drug-drug interactions 
were reported. 
 
(ii) Ion-containing antacids 
 
Antacids, aluminum, calcium, zinc, or magnesium containing or 
iron supplements or sucralfate (e.g.,carafate) may interfere with 
absorption of sparfloxacin into the body.  
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The concomitant administration of aluminum hydroxide 1gm with 
sparfloxacin 200 mg to six healthy volunteers decreased the 
Cmax, AUC and urinary excretion of sparfloxacin by 22, 35 and 25 
%, respectively. Among quinolone antibacterial, sparfloxacin is 
the least inhibited by aluminum hydroxide. Similar reduction of 
sparfloxacin absorption has been reported when a mixture of 
aluminum hydroxide and magnesium hydroxide were used. 
 
(III) Fenbufen 
 
Unlike other fluoroquinolones sparfloxacin does not cause any 
interaction when administered simultaneously with Fenbufen. 
 
Use of tricyclic antidepressants (amitriptyline, amoxapine, 
clomipramine, desipramine, doxepin, imipramine, nortriptyline, 
protriptyline, triimipramine) with sparfloxacin may lead to an 
increased risk of heart rhythm problems caused by sparfloxacin or 
these medicines.  
 
Place of sparfloxacin in therapy 142 
 
Sparfloxacin is a broad spectrum antibacterial. The mechanism of 
action of sparfloxacin is similar to other fluoroquinolones. The 
drug has a potent activity against many organisms, such as Gram-
positive bacteria including Streptococcus pneumoniae and 
Methicillin-resistant Staphylococcus aureus, Gram-negative 
bacteria, glucose nonfermenters, anaerobes, legionelia sps. 
Chlamydia sps. and mycobacterium sps. In general, in vitro 
potency of Sparfloxacin against Gram-negative bacteria is similar 
to that of CPFX and higher than those of OFLX, ENX and NFLX. 
The range of activities against families other than the Gram-
negative bacilli is superior to the above four quinolones.  
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The Cmax and AUC of sparfloxacin increase dose-relatedly with 
increasing oral doses of up to 400 mg. The t1/2 of sparfloxacin 
(about 15 to 20 hours) is longer than that of other quinolones. 
 
These pharmacokinetic properties of sparfloxacin, in combination 
with pharmacological characteristics, permit once daily therapy. 
Sparfloxacin 200 mg once daily is effective in the treatment of 
various bacterial diseases, such as respiratory tract infections, 
bacterial pneumonia, infectious enteritis, tract infections, skin and 
soft tissue infections, sexually transmitted diseases, suppurative 
otitis media and surgical infections. The results from the initial 
comparative, double blind clinical trials with sparfloxacin have 
shown high clinical efficacy in treatment of community acquired 
pneumonia (88%), acute exacerbation of chronic bronchitis (79%) 
and acute purulent sinusitis (80%). 
   
Side effects 143,144 
 
Along with its needed effects, a medicine may cause some 
unwanted effects. Although not all of these side effects may occur, 
if they do occur they may need medical attention. 
 
More common: Blisters; itching; redness of skin; sensation of skin 
 burning; skin rash; swelling of skin.   
     
 Rare: Abdominal or stomach cramps and pain (severe); abdominal 
tenderness; diarrhoea (watery and severe), which may also be 
bloody; fever; pain, inflammation, or swelling in calves, shoulders 
or hands, Acute-psychosis; agitation; confusion; hallucinations  
(seeing, hearing, or feeling things that are not there); tremors. 
 
Less common:  Irregular heart beat   
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Other side effects may occur that usually do not need medical attention 
includes diarrhoea; dizziness; drowsiness; headache; light-
headedness; nausea; nervousness; trouble in sleeping; vaginal itching 
and discharge; vomiting.  
 
Other medical problem 
 
Brain or spinal cord disease, including hardening of the arteries in 
the brain, or epilepsy or other seizures; sparfloxacin may increase 
the chance of convulsions (seizures) occurring.  
• Sparfloxacin can cause heart rhythm problems.  
• Kidney disease; Effects of sparfloxacin may be increased 
because of slower removal from the body.  
• Sensitivity of the skin to sunlight (previous);Increased risk of 
severe reactions to sunlight caused by sparfloxacin. 
  Dosing  
Adults 400 mg on the first day, then 200 mg once a day for an 
additional nine days.  
 
Precautions 
  
Sparfloxacin has not been studied in pregnant women and 
children. However, this medicine has been shown to cause bone 
development problems in young animals.  
 
Review of methods of analysis 
 
Sparfloxacin is not official in any pharmacopoeia. 
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HPLC145-149, HPTLC150, Spectrophotometric151-159, 
Fluorimetric160,161 Voltametric methods162,163 for analysis of 
sparfloxacin have been reported.  
 
Borner et al146 have published method of determination of 
sparfloxacin in serum and urine by high-performance liquid 
chromatography. Serum proteins were removed by precipitation 
with acetonitrile after the addition of ofloxacin as an internal 
standard. The supernatant solvent was evaporated in a vacuum 
concentrator and the dry residue was redissolved in the mobile 
phase. Separation was performed on a cation-exchange column 
(Nucleosil 100 5SA, 125 x 4.0 mm I.D., 5 microns particle size) 
protected by a guard column (Perisorb RP-18, 30 x 4.0 mm I.D., 
30-40 microns particle diameter). The mobile phase consisted of 
750 ml of acetonitrile and 250 ml of 100 mmol/l phosphoric acid 
(v/v) to which sodium hydroxide had been added. The final 
concentration of sodium was 23 mmol/l and the pH was 3.82. 
Sparfloxacin and ofloxacin were detected by spectrofluorimetry 
(excitation wavelength 295 nm; emission wavelength 525 nm). 
The flow-rate was 1.5 ml/min and the retention times were 4.7 
(sparfloxacin) and 8.0 (ofloxacin) min.  
 
Michael et al147 have described defluorinated sparfloxacin as a 
new photoproduct identified by liquid chromatography coupled 
with UV detection and Tandem Mass Spectrometry. 
 
Herida and Marona148 have also reported method of stability study 
determination of sparfloxacin and its degradation product by 
HPLC-PDA. 
 
He et al149 have reported method for the separation and 
determination of sparfloxacin by HPLC. The sample was dissolved 
in a mixture of acetonitrile: water (1:1). Operating conditions were 
as follows: mu-Bondapak C18 column (300 x 3.9 mm), V 
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(acetonitrile): V (methanol): V (2 mmol/L H3PO4), adjust pH 3.5 
with triethylamine) = 30:5:65 as mobile phase with a flow rate of 1 
ml/min, UV detection at 278 nm, and column temperature was 
15˚C. Under the above conditions, sparfloxacin and other 
impurities were separated from each other.  
 
Cao et al150 have described analytical method for the quantitative 
determination of sparfloxacin injection by HPLC. The analytical 
conditions were as follows. A Waters Symmetry C18 (5 microns, 
150 x 3.9 mm i.d.) Column was used as the analytical column. The 
detection wavelength was UV-298.8 nm. The column temperature 
was 30˚C. The mobile phase was 0.2% KH2PO4 buffer (pH 3.2); 
Acetonitrile : Methanol (80:15:5, volume ratio) and the flow-rate 
was 1.0 ml/min. The injection volume was 10 µl. The linear range 
(the peak area vs the mass concentration of sparfloxacin) was 
from 39.94 mg/l to 199.68 mg/l and the correlation coefficient was 
0.9999. The average recovery of sparfloxacin was 100.1% (n = 5), 
and its RSD was 0.72%.  
 
Kowalczuk et al151 have reported a solid-phase extraction (SPE) 
procedure for extraction of relatively hydrophilic amphoteric drugs 
from plasma coupled with their determination by high-performance 
liquid chromatography .The extraction columns filled with 500 mg 
of reversed phase octadecyl bonded silica phase were conditioned 
with methanol, water, and ammonium acetate solution. After 
sample application, the sorbent was washed with the same 
solution. The analyte was then desorbed with the methanol–
acetate buffer (pH 2.8) mixture. The absolute recovery of 
sparfloxacin was 92%. 
 
Mody et al152 have developed HPTLC method for the 
measurement of sparfloxacin in human plasma and its use for 
pharmacokinetics study has been evaluated. A known amount of 
the plasma extract was spotted on precoated silica gel G F254 
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plates using a Camag Linomat IV auto sampler. Sparfloxacin was 
quantified using a Camag TLC Scanner 3. The recovery study of 
authentic analytes added to plasma at 0.1 to 0.8 mg/ml was 
94.9±0.98% and the lowest amount of sparfloxacin that could be 
detected was 50-ng/ml plasma. The method was used for the 
determination of plasma levels as well as pharmacokinetics 
parameters of sparfloxacin after oral administration. 
 
Kowalczuk et al have reported comparison of HPLC and Classical 
and Derivative UV-spectrophotometric methods for the 
quantification of sparfloxacin153.  
 
Herida and Marona154 have published UV spectrophotometric 
method of sparfloxacin in tablet. Solutions of sparfloxacin powder 
in methanol (1.0 mg/l) were prepared. The absorbance value of 
solution was measured at 292 nm. The tablets powder was treated 
with methanol; mechanically shaken for 30 min. And diluted with 
sterile distilled water to give a final estimated concentration of 6.0 
mg/l. The reproducibility of method reported was 97.08 ± 1.07 % 
(n = 6). The method gave rise to linear data in the range 2–12 
mg/l with accuracy and precision in the range of 0.56–3.01 %.   
 
Meyanathan et al155 have published spectrophotometric analysis 
of sparfloxacin in its dosage forms.  
 
Girish et al156 have developed two visible spectrophotometric 
methods (Method A and Method B) for the determination of 
sparfloxacin in bulk and in formulations. Method A was based on 
the reaction of sparfloxacin with ferric nitrate reagent to form a 
yellow colored chromogen with an absorption maximum of 440 nm 
and Method B was based on the condensation of sparfloxacin with 
P-dimethyl amino benzaldehyde under acidic conditions to produce 
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a colored schiff's base with an absorption maximum of 455 nm. 
Recovery in both the methods was 98-101%.  
 
Marona and Schapoval157 have described a visible light 
spectrophotometric method for the determination of sparfloxacin in 
tablets. The procedure was based on the complexation of 
bromothymol blue 0.5% and sparfloxacin to form a compound of 
yellow color with maximum absorption at 385 nm. The Lambert-
Beer’s law was obeyed in the concentration range of 2-12 mg/l.  
 
Kuchekar et al158 have reported spectrophotometric estimation of 
sparfloxacin in tablets. Two methods have been developed for 
estimation of sparfloxacin in tablets. Method A was based on the 
reduction of ferric ions to ferrous ions by the drug, which further in 
presence of potassium dichromate as oxidizing agent produced 
green chromogen measured at 680 nm against reagent black. The 
chromogen obeyed linearity over 1.5 to 5.5 µg/ml. Method B was 
based on similar reaction using ferric nitrate and potassium 
ferricyanide which produced blue chromogen measured at 720 nm 
against reagent blank, the chromogen obeyed linearity over 1.5 to 
4.0 µg/ml.  
 
Rao159 has developed spectrophotometric method for 
determination of sparfloxacin by using reagent p-
dimethylaminobenzaldehyde.  
 
Wang160 has reported spectrofluorimetric determination of trace 
amounts of europium (III) ion with lutetium (III)-sparfloxacin-
sodium dodecyl sulfate luminescence enhancement system. It is 
reported that Luminescence-enhancement system was based on 
complex formation between europium and sparfloxacin in the 
presence of lutetium in a sodium dodecyl sulfate-solution. 
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Wei et al161 have discovered a new lanthanide-sensitized 
luminescence system: europium–sparfloxacin–1,10-
phenanthroline–sodium dodecyl sulfate. Under the optimum 
conditions, the fluorescence intensity of the system was found 
linear function of the concentration of europium in the range 
5.0×10–9 – 1.0×10–6 mol L–1 and the detection limit reported is 
1.0×10–10 mol L–1. The system was used for the determination of 
trace amounts of europium in rare earth samples with satisfactory 
results.  
 
Reddy et al162 have developed electrochemical determination of 
sparfloxacin in pharmaceutical formulations and urine samples 
using a β-cyclodextrin modified carbon paste electrode. The 
electrochemical behavior of sparfloxacin at β-cyclodextrin 
modified carbon paste electrode (CDMCPE) had been studied. 
Compared with bare carbon paste electrode (CPE), the β-
cyclodextrin modified carbon paste electrode exhibited a marked 
enhancement of current response of sparfloxacin. Cyclic 
voltametric (CV) studies indicated that the process was 
irreversible and adsorption controlled. A linear calibration plot was 
obtained over the 0.043–60 µM range with a correlation coefficient 
of 0.9990 in ph 3.0. Britton Robinson buffer with a detection limit 
of 0.04 µM by using DPV. The peaks from the techniques CV and 
DPV are attributed to the complex formation of quinone group of 
the drug with β-cyclodextrin.  
 
Jai et al 163 have reported an electrochemical analysis (direct 
current polarographic (DCP) and differential pulse polarographic 
(DPP methods) of sparfloxacin in pharmaceutical formulations and 
biochemical screening of its Co (II) complex. Sparfloxacin forms a 
complex with Co (II), which was characterized on the basis of 
elemental analysis, IR spectral, polarographic and amperometric 
analysis. The analytical results indicated a 1:1 (M:L) stoichiometry 
for the Co (II)-sparfloxacin complex. The antibacterial studies on 
                                                                                                                          Sparfloxacin        
    140
the drug and its complex were carried out against various 
pathogenic bacteria. The results revealed that the complex was 
more potent compared to the pure drug.  
 
Review of tablet dissolution test 164-166 
 
Dissolution testing has been emerged as a single most important 
test to ensure quality of the product when carried out 
appropriately. Knowledge of theoretical as well as practical 
aspects of dissolution testing proved to be very important for 
pharmacecutical scientist engaged in product development and 
quality control. Since the dissolution rate of a drug from its dosage 
form can often become the rate limiting process in the bio-
availability, efforts have been laid down in the development of 
reliable in vitro test methods that can mimic the in-vivo conditions.  
 
Objectives of dissolution test 
 
(1) As quality control tool 
(2) In the development of new drug products. 
(3) To assists in the determination of bioavailability and 
bioequivalence. 
(4) For characterising the biopharmaceutical quality of a 
product at different stages of life cycle. 
(5) For choosing between different alternative formulation 
candidates. 
(6) As a supportive in the evaluation and interpretation of 
possible risks. 
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Official apparatuses 
 
USP App -I 
It can be used for the dissolution testing of capsules. It consists of 
the following : 
• A covered vessel made up of glass or other inert 
transparent material 
• A motor assembly 
• A metallic drive shaft 
• A cylindrical basket - 40 mesh (USP) 
• A suitable water bath in which vessel can be partially 
immersed and have capacity to maintain specified temp 
inside the vessel 
 
USP App –II 
It is used for the dissolution testing of tablets. It consists of the  
Following : 
• Paddle and shaft as a Stirring element 
• A small, loose piece of non - reactive material (few turns of 
wire helix) may be attached to dosage units that would 
otherwise float 
• All others points, (from (1) to (3)) are same as in App 1 
 
USP App –III 
It is used for the dissolution testing of extended release dosage 
forms.  
The assembly consist of 
• A set of cylindrical flat bottomed glass vessel  
• A set of glass reciprocating cylinders 
• Stainless steel fittings and polypropylene screens to fit tops 
and bottoms of the reciprocating cylinders 
• A motor and a drive assembly 
• A water bath 
• Distance traveled by the reciprocating cylinder during the 
upward and downward stroke 9.9 - 10.1 cm 
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USP App –IV 
           It is used for dissolution testing of delayed release dosage forms. 
           It consists of 
• A Reservior 
• A pump for dissolution medium 
• A flow through cell 
• A water bath 
• Delivery range of the pump is 240 - 960 ml\hr. Flow rate is 
4.8 and 16 ml/min 
• Bottom cone filled with small glass beads of 1mm diameter        
of which one bead is of about 5 mm positioned at apex to 
protect the fluid entry tube 
• A tablet holder for positioning of special dosage forms eg, 
inlay tablets 
 
USP App –V 
It is used for dissolution testing for transdermal dosage forms. 
• It consists of stainless steel disc assembly in addition to 
paddle apparatus for holding transdermal dosage forms. 
 
USP App –VI 
It is used for dissolution testing for transdermal dosage forms.     
• Basket is replaced and a shaft with a stainless steel cylinder 
stirring element and a water bath to maintain specified temp 
during test. Dosage form is spreaded on the cylinder in form 
of flat film. 
 
 
USP App- VII 
It is used for dissolution testing of variety of dosage forms such as 
transdermal dosage forms and solid dosage forms. 
• It cosists of :A set of reciprocating disc shaped sample 
holders 
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Testing conditions  
 
(1) Dissolution medium 
 
Composition: Generally water is used as solvent for the 
dissolution medium but pH and surface tension of pure water 
varies depending upon source of water ph may change due to 
absorption of CO2 from air. Addition of organic solvents are 
generally avoided. 
 
pH: It should be in between 1- 6.8. For low pH 0.1 N HCl is used. 
For high pH (4.5 - 8.0 pH )- USP buffers are used. 
 
Volulme: USP specifies it in between 50 ml - 1000 ml. Generally 
900 ml is used. For poorly soluble drugs 4000 ml can be used but 
it is considered as modification . 
 
Agitation: It should be in between 50-100 rpm but should not be 
more than 150. In flow through cell flow rate should be 4,8 or 16 
ml/min. 
 
Temperature: It should be 37±0.5°C for solid dosage forms and 
32±0.5°C for transdermal dosage forms. 
 
Deaeration: It should be done by suitable validated method.  
 
(2) Qualification and validation  
 
Apparatus suitability test (AST) with calibrators is a further 
important aspects of qualification and validation. The use of USP 
calibrator tablets (disintegrating and non-disintergrating) is 
recommended. System suitability test of USP App -3 has to be 
performed with both multiparticulate and a monoparticulate 
standard formulation. AST are recommended to be performed not 
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less than twice per year per equipment and after any occasion of 
equipment change, significant repair or movement. 
Validation of  dissolution tests for solid dosage forms 
? Specificity 
? Accuracy   
? Filter bios calculations 
? Precission and ruggedness 
? Geometrical and dimensional accuracy 
 
(3) Dissolution specifications 
 
They are set to ensure batch-to-batch consistency with the range, 
which guarantees acceptable biopharmaceutical performances in 
vivo. For immediate and very fast drug releasing dosage form in a 
single point test at least 80% of the drug substance  is dissolved 
in 15 min under reasonable justified test conditions. 
 
For controlled release - At least three points are required.  
1st specification point - To prevent dose dumping it should be set 
after a testing interval of one or two hours or corresponding to a 
dissolved amount  of 20-30 % of labeled drug substance. 
 
2nd Specification point - It should define the dissolution pattern 
and thus be around 50 % release of labeled drug substance. 
3rd specification point - It should release quantitative drug 
release generally > 80 %. 
 
The dissolution run in quality control should be extended for the 
time interval  at atleast 80 % of drug substance is dissolved. 
 
Shorter time test intervals can be acceptable in special cases. 
 
(4) Factors affecting dissolution time 
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Factors related to the physicochemical property of drug 
 
• Solid phase characteristics  
• Polymorphism 
• Amorphous / crystal state  
•  Free or salt form 
• Complexation, eutectics  
•  Particle size 
• Surfactants 
 
Excipients and additives 
 
• Granulating agents and binders  
• Disintegrating agents 
• Lubricants 
• Surfactants 
 
Factors related to dosage forms 
  
• Granule size 
• Drug excipients interactions 
• Compression force 
• Deaggregation 
• Storage of dosage forms 
 
Factors related to the dissolution testing devices 
 
• Eccentricity of agitating element  
• Vibration  
• Agitation intensity 
• Stirring element alignment  
•  Flow pattern disturbances  
• Sampling probes, position and filter 
• Dosage form position 
• Type of device 
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Factors related to dissolution test parameter 
 
? Temperature 
? Dissolution medium (composition, viscosity, dissolution) 
   
 Miscellaneous factors 
 
? Adsorption 
? Sorption 
 
(5) In vitro dissolution testing of water insoluble drugs 
 
Dissolution of drugs from the given dosage form particularly solid 
dosage forms is a necessary criterion for drug bioavailability i.e. 
The drug must be solubilized in the aqueous environment of GIT 
in order to be absorbed. 
 
For water soluble drug dissolution is not a problem as due to their 
hydrophilic nature they get easily dissolve in gastrointestinal fluid 
and get absorbed quickly. But in case of water insoluble drugs, 
dissolution of the drug from the given dosage form is a rate 
limiting step for oral absorption and consequently for the 
bioavailability. 
 
In vitro testing of water insoluble drugs earlier only water was 
used. It was found that predicted bioavailability was quite lower 
than observed. Reason was investigated that it was due to the 
presence of lecithin and bile salts forming mixed micelles into 
which drug was solubilized. As a result in vitro dissolution medium 
was modified using surfactants and bile salts so as to produce in 
vivo conditions as it mimics the physiological fluid media 
containing mixed micelles of bile salts and lecithin. 
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Surfactants act by three mechanisms, Wetting, Micelle 
solubilization and Deflocculation. With increase in concentration of 
SLS, rate and extent of dissolution also increase. But low levels of 
surfactants are recommended, as this seems to give better In 
Vivo-Vitro Correlation. 
 
The dissolution test is used to determine compliance with the 
dissolution requirements where stated in the individual monograph 
for a tablet. Of the two types of apparatus described in USP, the 
one specified in the individual monograph is used. The solvent is 
also specified in individual monograph. If the dissolution solution 
is buffer solution the pH is adjusted with in 0.05 unit of the ph 
specified in the individual monograph. Where a single time 
specification is given the test may be concluded in a shorter 
period if the requirement for minimum amount dissolved is met. If 
two or more times are specified, specimen are to be withdrawn 
only at the stated times, within a tolerance of   2% and analyzed 
by suitable analytical procedure. 
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5.2  Experimental 
 
5.2.1  Spectrophotometric determination of sparfloxacin 
 
5.2.1.1 Apparatus 
 
Double Beam spectrophotometer Shimadzu 1601 model having 
two matched cells with 1 cm light path was used for spectral 
measurements. 
 
Single pan Shimadzu Libror AEG-220, analytical balance was 
used for weighing had a sensitivity of one tenth of milligram. 
  
5.2.1.2 Materials and reagents 
   
Sparfloxacin (Gift sample from Helios Pharmaceutical, Kadi, India), 
sodium nitrite (E. Merck), hydrochloric acid (E. Merck), ammonium 
sulfamate (E. Merck), sodium hydroxide (E. Merck), methanol (E. 
Merck). N-(1-naphthyl) ethylene diamine dihydrochloride (E. 
Merck) and double distilled water. 
 
All the reagents, chemical and solvents used in the study were of 
the analytical reagent grade. 
 
     Sparfloxacin tablets were procured from local market. 
 
Sodium nitrite solution (0.2 % w/v) 
 
An accurately weighed sodium nitrite (200 mg) was dissolved in 
and diluted to 100 ml with water. 
 
Sodium hydroxide solution (0.5 N) 
 
Sodium hydroxide (2.0 gm) was weighed accurately and dissolved 
in and diluted to 100 ml with water. 
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          Hydrochloric acid solution (1 in 10)  
 
Hydrochloric acid (35 % pure, Sp. Gr. 1.18) 1 ml was added to 10 
ml water. 
 
Ammonium sulfamate solution (1.0 % w/v) 
 
Accurately weighed ammonium sulfamate (1.0 gm) was dissolved 
in and diluted to 100 ml with water. 
 
N-(1-Naphthyl) ethylenediamine dihydrochloride reagent (0.2 %) 
 
An accurately weighed N-(1-Naphthyl) ethylene diamine 
dihydrochloride (200mg) was dissolved in and diluted to 100 ml 
with water. 
    
 Standard solution of sparfloxacin 
 
An accurately weighed sparfloxacin  (50 mg) was transferred into 
25 ml volumetric flask and dissolved in sodium hydroxide (5.0 ml). 
Volume was adjusted up to the mark with methanol. The solution 
(2.5 ml) diluted further to 25 ml with methanol. The final solution 
contained 200 µg of sparfloxacin per ml of the solution. 
 
5.2.1.3 Determination of absorption maxima 
 
Into a 10 ml volumetric flask, standard sparfloxacin solution (1.0 
ml), methanol (2.0 ml), hydrochloric acid solution (1.0 ml) and 
sodium nitrite solution (1.0 ml) were pipetted successively, mixed 
and allowed to stand for 3 minutes. Ammonium sulfamate solution 
(2.0 ml) was added, mixed and allowed to stand for 3 minutes. To 
the reaction mixture Bratton-Marshal reagent (BMR) solution (2.0 
ml) was added, mixed and allowed to stand at 25° C for 30 
minutes. The final volume was adjusted with methanol. 
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Absorbance of the colored solution was scanned on double beam 
shimadzu model 1601 spectrophotometer from 800-400 nm 
against reagent blank solution.  
 
Maximum absorbance was obtained at 585 nm. (Fig. 5.1) 
 
5.2.1.4 Lambert-Beer’s standard curve for sparfloxacin 
 
Into a series of 10 ml volumetric flasks, standard sparfloxacin 
solution (0.1, 0.2, 0.5, 1.0, 2.0 and 3.0 ml) was transferred. The 
total volume in the flask was adjusted to 3.0 ml with methanol. 
Hydrochloric acid solution (1.0 ml) and Sodium nitrite solution (1.0 
ml) were pipetted successively, mixed and allowed to stand for 3 
minutes. Ammonium sulfamate solution (2.0 ml) was added, mixed 
and allowed to stand for 3 minutes swirling occasionally. To the 
reaction mixture Bratton-Marshal solution (2.0 ml) was added, 
mixed and allowed to stand at 25° C for 30 minutes. The final 
volume was adjusted with methanol. Absorbance of the colored 
solutions was measured at 585 nm against reagent blank.  
 
The Lambert- Beer’s law was obeyed in the concentration range of 
2.0 to 60 µg of sparfloxacin per ml of solution. (Fig.5.2) 
 
5.2.1.5 Optimization of analytical parameters 
  
Effect of concentration of methanol 
 
Into a series of 10 ml volumetric flasks, standard sparfloxacin 
solution (1.0 ml), volumes in flask was made up with methanol 
(1.0, 2.0, 3.0,4.0 ml), hydrochloric acid (1.0 ml) and Sodium nitrite 
solution (1 ml) were pipetted successively, mixed and allowed to 
stand for 3 minutes. Ammonium sulfamate solution (2.0 ml) added 
to each flask, mixed and allowed to stand for 3 minutes swirling 
occasionally. To the flask Bratton-Marshal reagent solution (2.0 
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ml) was added, mixed and allowed to stand at 25° C for 30 
minutes. The volume of final solution was adjusted with methanol. 
The blank solution was prepared in the similar manner replacing 
the drug solution by equal volume of methanol.  
 
Absorbance of the colored solutions was measured at 585 nm 
against reagent blank. 
 
The maximum absorbance was observed in presence of 3.0 ml of 
methanol, which includes methanol present in standard solution of 
drug. On further increasing the volume of methanol color intensity 
was decreased. (Fig. 5.3) 
 
Effect of concentration of hydrochloric acid 
 
Into a series of 10 ml volumetric flask, standard solution of 
sparfloxacin (1.0 ml), methanol (2.0 ml), different volumes of 
hydrochloric acid (0.5, 1.0, 1.5, 2.0 ml) and sodium nitrite solution 
(1.0 ml) were pipetted successively and analyzed as described in 
5.2.1.4.  
 
The maximum absorbance was observed in presence of 1.0 ml of 
hydrochloric acid solution, which decreases on further increasing 
the concentration of the hydrochloric acid solution. (Fig. 5.4) 
 
Effect of concentration of ammonium sulfamate solution 
 
Into series of 10 ml volumetric flasks, standard solution of 
sparfloxacin (1.0 ml), methanol (2.0 ml), hydrochloric acid (1.0 ml) 
and sodium nitrite solution (1.0 ml) were pipetted successively, 
mixed and allowed to stand for 3 minutes. Different volumes of 
ammonium sulfamate solution was added (0.5, 1.0, 2.0, 2.5 ml), 
mixed and allowed to stand for 3 minutes swirling occasionally. To 
the reaction mixture Bratton-Marshal reagent solution (2.0 ml) was 
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added, mixed and allowed to stand at 25°C for 30 minutes. The 
final volume was adjusted with methanol. Absorbance of the 
colored solutions was measured at 585 nm against reagent blank 
solution.  
 
The maximum absorbance was observed in presence of 2.0 ml of 
ammonium sulphamate solution, which remained constant on 
further increasing the concentration of the ammonium sulfamate 
solution. (Fig. 5.5) 
 
Effect of concentration of Bratton-Marshal reagent 
 
Into series of 10 ml volumetric flasks, standard solution of 
sparfloxacin (1.0 ml), methanol (2.0 ml), hydrochloric acid (1.0 ml) 
and sodium nitrite solution (1.0 ml) were pipetted successively, 
mixed and allowed to stand for 3 minutes. Ammonium sulfamate 
solution (2.0 ml) was added to each flask, mixed and allowed to 
stand for 3 minutes swirling occasionally. To the solution different 
volumes of Bratton-Marshal regent solution (0.5, 1.0, 2.0, 2.5 and 
3.0 ml) was added, mixed and allowed to stand at 25° C for 30 
minutes. The final volume was adjusted with methanol. 
Absorbance of the colored solutions was measured at 585 nm 
against the blank solution. 
  
The maximum absorbance was observed in presence of 2.0 ml of 
Bratton-Marshal reagent solution, which remains constant on 
further increasing the concentration of the reagent. (Fig. 5.6) 
 
Time for maximum color development and color stability 
 
Reaction mixture was prepared as per the procedure described 
under 5.2.1.4 and allowed to stand for different time interval (10, 
20, 30,40, 50, 60, 70 minutes). The final volume was adjusted with 
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methanol. Absorbance of the colored solution was measured at 
585 nm against the reagent blank.  
 
Maximum absorbance was observed at 30 minutes, which 
remained constant for more than 2 hour. (Fig. 5.6) 
 
5.2.1.6 Determination of sparfloxacin in bulk powder 
         
Accurately weighed sparfloxacin (50 mg) dissolved in sodium 
hydroxide solution (5 ml) and diluted to 25 ml with methanol. The 
solution (5 ml) diluted further to 50 ml with methanol. The solution 
(1.0 ml) analyzed as described under 5.2.1.4. 
 
The amount of sparfloxacin was determined by referring to the 
standard curve. (Table 25) 
  
5.2.1.7 Determination of sparfloxacin in tablets 
 
Twenty tablets of sparfloxacin were weighed and powdered. A 
quantity of the powder equivalent to 50 mg of sparfloxacin was 
treated with sodium hydroxide solution (5ml) in a 25 ml volumetric 
flask. Methanol (10 ml) added, and the solution sonicated for 30 
minutes. The volume was adjusted with methanol and filtered 
through sintered glass funnel. Rejecting first few ml, the filtrate 
(1.0 ml) diluted to 10 ml with methanol. The resulting solution (1.0 
ml) analyzed as described in 5.2.1.4.  
 
The amount of sparfloxacin was determined by referring to the 
standard curve. (Table 26) 
 
Validation of the methods 
The method was validated in terms of linearity, precision and 
accuracy.  
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? Linearity between absorbance and concentration by 
Regression analysis. 
?  Precisions by performing parallel determination on intraday 
and inter day bases.  
? Accuracy by recovery study by standard addition method  
 
5.2.2  Dissolution study of sparfloxacin tablets 
 
5.2.2.1 Apparatus used 
 
For dissolution ELECTROLAB make Programmable Tablet 
Dissolution Tester MODEL TDT-06P (USP XXII) 
 
Specification: USP Apparatus II  
 
Display   : 3 digit LED Display 
Speed range  : 30 to 200 rpm. 
Resolution   : 1 RPM    
Accuracy   : ± 1 RPM . 
Temperature range : 30 to 40 °C 
Resolution   : 0.1 °C 
Accuracy   : ± 0.2 °C 
Bath Size :610 mm (W) X 325mm (D) X 230mm (H) 
Material : 8 mm Thick Acrylic 
Timer setting range   : 0.01 to 99.59 min 
      Accuracy                       : ± 0.1%. 
 
For estimating the dissolved drug double beam spectrophotometer 
Shimadzu Model 1601 was used. 
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5.2.2.2 Dissolution test 
 
Dissolution conditions 
 
 SET-1 SET-2 
Dissolution 
medium 
Aqueous-
Phosphate buffer 
(pH=7.6) 
900 ml 
Aqueous-Acetate 
buffer 
 (pH=4.0) 
 900 ml 
Stirring speed 100 rpm 50 rpm 
Temperature   37+ 0.1 °C 37 ± 0.1 °C 
 
 
Dissolution procedure  
 
Sparfloxacin film coated tablets (Zospar/ Sparflo) containing 200 
mg sparfloxacin were introduced into the each of the six 
dissolution chambers containing 900 ml dissolution medium, 
maintained at 37 + 0.5°C and stirred at speed of 100 rpm. 
Dissolutions (5 ml) were withdrawn at an interval of (a) 15 minutes 
for 120 minutes for set-1 and (b) 10 minutes for 60 minutes from 
all six chambers. The dissolutions were filtered through sintered 
glass funnel.  
 
Test preparation  
 
Filtrate of the dissolution (1.0 ml) diluted to 10 ml with the 
respective dissolution medium. 
 
Standard preparation 
 
An accurately weighed sparfloxacin (50mg) was transferred into 
25 ml volumetric flask containing sodium hydroxide solution (5ml) 
and dissolved. The volume was adjusted up to the mark with 
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methanol. The solution (1.0 ml) diluted to 10 ml with methanol. 
This solution (1.0 ml) diluted further to 10 ml with the dissolution 
medium. The final solution contained 20 µg/ml. 
 
The test and standard preparation were analyzed by BMM as 
described under 5.2.1.4 as well as by UV spectrophotometry 
described below. 
 
UV spectrophotometry  
 
Absorbance of test and standard preparation was measured at 
290 nm against dissolution medium as blank solution. 
 
%  Dissolution was calculated using the formula;  
   
           % Dissolution = (Atest / Astd) x Cstd x Vd x10-5 x L 
  
Where A test and Astd are Absorbance of test and standard 
preparation respectively, Cstd = concentration of sparfloxacin in 
standard preparation, Vd =Volume of dissolution medium (900 ml), 
L is Label value sparfloxacin tablet in milligrams. (Table 30-33) 
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5.3 Results and Discussion 
 
Spectrophotometric determination of sparfloxacin  
 
N-(1-Naphthyl)ethylenediamine dihydrochloride have been widely 
used for determination of primary aromatic amines as coupling 
reagent in azo-dye formation.  
 
Bardelin et all61 developed spectrophotometric method for 
determination of procainamide in the range 0.5 to 25 µg/l in plasma 
using Bratton Marshall Reagent. Ethanol was used to eliminate 
excess of nitrous acid. 
 
Bratton-Marshal reagent had been used in the assay of 
Sulphacetamide sodium ophthalmic solution USP 2068. 
 
Schwartz et al62 have reported practical screening procedure for 
Sulfathiazole in honey using Bratton Marshall reagent. 
 
Sparfloxacin contains a primary aromatic group. In the present 
method, it is diazotized and coupled with Bratton-Marshal reagent 
to give blue colored solution. 
 
Initially the reaction was tried in aqueous medium. Although 
diazotization of sparfloxacin was observed in aqueous medium but 
subsequent coupling with Bratton-Marshal reagent was not instant. 
However the reaction mixture was kept overnight. Next morning 
insoluble violet-blue product was observed at the bottom of the 
flask. The violet-blue product was found soluble in methanol. 
Hence reaction was tried in methanol. Formation of violet-blue 
chromogen was instant in methanol.  
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Finally standard solution of sparfloxacin was prepared in methanol. 
The sparfloxacin was diazotized with sodium nitrite in presence of 
aqueous hydrochloric acid (1 in 10) and methanol. Excess nitrous 
acid was neutralized by ammonium sulfamate. To this aqueous 
solution of Bratton marshal reagent was added. Reaction was 
carried out at an ambient temperature of 25 ˚C. Violet-blue colored 
chromogen was produced. The final volume was adjusted with 
methanol. The pH of resulting solution was 1.0. The solution was 
scanned for absorbance in visible range. The absorption spectrum 
showed maximum absorbance at 585 nm. (Fig.5.1) 
 
Beer's law is obeyed in concentration range of 2.0-60 µg of 
sparfloxacin per ml of reaction mixture. (Fig. 5.2) 
 
The effect of concentration of the reagents, solvents and time of 
reaction, on development and intensity of color were studied and 
optimized.  
 
In the present method maximum intensity of color was produced at 
an optimum volume of methanol (3.0 ml), sodium nitrate solution 
(1.0 ml), hydrochloric acid solution (1.0 ml), ammonium sulfamate 
solution (2.0 ml) and Bratton-Marshal reagent (2.0 ml). (Fig.5.3-
5.6) 
 
The optimum time of reaction after addition of sodium nitrate 
solution and ammonium sulfamate solution was found 3 minute for 
both the reaction. After addition of Bratton-Marshal reagent, the 
color intensity of the reaction mixture continued to increase with 
time. Maximum color was obtained at 30 minutes. The chromogen 
was observed to be stable for 2 hours at room temperature.  (Fig. 
5.7)  
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Bulk powder of sparfloxacin and its formulations were analyzed by 
proposed method. The results are comparable with those obtained 
by reported methods154. (Table 25, 26) 
 
Proposed reaction mechanism 
 
In the determination, sparfloxacin is diazotized by sodium nitrite in 
presence of hydrochloric acid and methanol. The excess nitrous 
acid is neutralized by ammonium sulfamate. The diazotized-
sparfloxacin is then coupled with Bratton-Marshal reagent. A 
violet-blue colored chromogen is produced having maximum 
absorbance at 585 nm. Methanol probably catalyze coupling by 
acting as solvent for azo-dye formed in reaction, the azo-dye was 
found insoluble in water. 
 
N
NH
N
O
COOHF
CH3
CH3
NH2
F
NaNO2 + HCl
HONO
 
                                    
                                         Sparfloxacin 
 
N
NH
N
O
COOHF
CH3
CH3
N
F
N
Cl
NH
NH2
Methanol
                              
                Diazotized -sparfloxacin                           Bratton-Marshal Reagent 
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N
NH
N
O
COOHF
CH3
CH3
N
F
N
NH
NH2
HCl
 
 
5-[[4- (Ethylenediamino) naphthyl] azo] -1-cyclopropyl-7- (cis-3, 5-dimethyl-1-
piperazinyl)-6,8-difluoro- 1,4-dihydro-4- oxo- 3-quinolinecarboxylic acid  
 
 
Validation of the method 
 
Linearity between absorbance and concentration 
 
For finding the linearity of the proposed method, absorbance of 
the reaction mixture was measured at various concentrations. 
Beer’s curve plotted and regression analysis was performed using 
Microsoft Excel.  
 
The linear equation of sparfloxacin obtained was,   
  
   y  = 0.0231x - 0.0067   
                        Where y=absorbance     
         x=concentration in of sparfloxacin µg/ml 
 
The correlation coefficient (r2) obtained is 0.9999. Thus there exist 
excellent linearity between absorbance and the concentration of 
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sparfloxacin in the range of 2.0 to 60 µg per ml of the reaction 
mixture.  
 
Sensitivity 
  
Using the regression linear (y  = 0.0231x), Sandell’s sensitivity of 
the method and molar absorptivity of the chromogen were found 
0.0433 µg cm-2/0.001 AU and 9062 respectively.   
 
Precision 
 
Relative standard deviations in the determination were found 
0.98% and 1.13% in bulk drug and tablet respectively. (Table 25, 
26) This shows that the method is precise. 
 
For further evaluation of precision of the method, determination of 
bulk powder by proposed method was repeated five times intra 
day and inter day basis at three different concentration level of the 
drug. (Table 27) The coefficients of variance (COV) of the 
absorbance of two sets are compared by F-test. F was calculated 
by F = SA2 / SB2, where SA and SB are standard deviations of the 
coefficients of variance (COV) of the absorbance in two sets. The 
calculated F value (2.056) is less than the table value (7.71), at 
P=0.05 for df = 4 within sample and df=1 between sample, hence 
there is no significance difference in intra and inter day precision 
of the method. The COV was found within a range of 1.03 to 2.24 
% or Precision is 99.35% 
 
Accuracy 
 
Accuracy of analysis was determined by recovery study in which 
known amount of the standard drug was added to pre-analyzed 
tablets of two brands at three level and they were re-analyzed by 
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the proposed method. The determinations were repeated for five 
times at each level.  
 
The % recoveries of sparfloxacin in the determination of the drug 
in tablets were found in the range of 98.93 to 99.16. (Table 28) 
 
Selectivity 
  
Only primary aromatic amines can form azo compounds, therefore 
the primary aliphatic amines, secondary amines and tertiary amine 
are less likely to interfere at the λ max of 585 nm. Hence the 
method is selective to primary amines. 
 
The proposed method was applied fot estimation of sparfloxacin 
bulk powder and its tablet. The results are in good agreement with 
reported method154. 
 
None of the usual diluents, excipients and solvents employed in 
the formulation interferes in the determination of sparfloxacin by 
proposed method. 
 
        Characteristics of the proposed method are summarized. (Table 29) 
 
Thus the proposed method is precise, simple and sensitive. The 
method may be used for routine analysis of sparfloxacin in bulk 
powder and dosage form. 
 
Dissolution study of sparfloxacin 
 
Sparfloxacin tablet is not official in IP, BP, and USP. Hence an 
attempt was made to provide dissolution profile of the marketed 
product by the application of the proposed method (BMM) for the 
estimation of concentration of the dissolved sparfloxacin. 
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Dissolutions of sparfloxacin tablets were studied in aqueous 
mediums at pH 7.6 and at pH 4.0.  
 
The absorbance of sample solutions was measured by proposed 
colorimetric method at 585 nm and by UV method at 290 nm. The 
% dissolutions were calculated from absorbance data and 
presented in graphical form. (Fig.5.8 - 5.11) 
 
Set-I 
At pH 7.6, both the brands have shown maximum % dissolution at 
90-minute; in Zospar tablets it was found 68.32% by UV and 
67.68% by BMM; in case of Sparflo tablets it was found 71.15% by 
UV and 71.02% by BMM. (Table 30, 31) 
 
But at 60 minutes % dissolutions observed at pH 7.6 were in the 
range of 65 to 68%. This is less than USP requirement of 80% 
dissolution in 60 minutes. 
  
Set- II  
 
In the dissolution medium (pH 4.0), at 60 minutes in case of 
Zospar dissolution was observed 82.37% by UV and 82.17% by 
BMM methods. Where as in case of Sparflo tablet it was 84.89% 
by UV and 84.65% by BMM. (Table 32, 33) 
 
At 60 minutes % dissolution observed at (pH 4.0) it is more than 
USP requirement of 80%.  
 
From results of the dissolution study it is evident that both the 
brands have similar dissolution profile and both the methods of 
estimation have produced comparable results. But as colorimetry 
is more selective than UV-Spectrophotometry, the proposed 
method (BMM) may be used for dissolution study of sparfloxacin 
tablets. 
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 Fig.5.1 Absorption spectrum of colored product of sparfloxacin  
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  Fig. 5.2 Lambert -Beer’s curve of sparfloxacin   
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Fig. 5.3 Effect of volume of methanol on color intensity  
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Fig. 5.4 Effect of concentration of hydrochloric acid on color intensity  
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Fig. 5.5 Effect of concentration of ammonium sulfamate on color 
intensity  
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Fig. 5.6 Effect of concentration of Bratton-Marshal reagent on    
color Intensity 
 
 
 
 
                                                                                                                          Sparfloxacin        
    167
       
0.35
0.4
0.45
0.5
0 50 100 150
Time (Minutes)
A
bs
or
ba
nc
e 
at
 5
85
 n
m
 
 
      Fig. 5.7 Time for development of maximum color intensity and  
        color stability 
    
   
 
 
  Table 25: Estimation of sparfloxacin in bulk powder  
 
% Assay by Weight 
Taken (mgs)
 Proposed Method   Reported method
154
40 97.25 96.23 
45 98.34 98.52 
50 99.11 98.21 
55 98.12 97.85 
60 99.78 99.11 
Mean  98.56 97.98 
% RSD 0.98 1.10 
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Table 26: Estimation of sparfloxacin in tablets  
 
% Assay* by 
Formulations
 
 
  Labeled 
value 
 
Proposed 
method  
Reported 
method154 
Tablets 
(Zospar) 
 
200 mg  
 
 
97.98± 1.14 
 
 
97.08 ± 1.07
 
Tablets 
(Sparflo) 
 
200 mg  
 
 
97.89±1.08 
 
 
97.13± 1.03
 
RSD  1.13 1.10 
  
 *Average of five determinations 
 
 
Table 27: Intra day-inter day precision in the 
determination of sparfloxacin  
       
Precision  
Intra day Inter day 
Concentration  
of 
Sparfloxacin 
(µg/ml) Absorbance*
±S.D. COV 
Absorbance* 
 ±S.D.  COV 
16 0.363±0.007 1.92 0.357±0.008 2.24 
24 0.543±0.011 2.03 0.544±0.009 1.65 
60 1.356±0.017 1.25 1.354±0. 014 1.03 
  
  *Average of five determinations ± S.D. 
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Table 28: Percentage recovery of sparfloxacin in formulation  
 
Formulation 
and label 
claim 
Amount of 
sparfloxacin 
in the tablet 
(mg) 
Amount of 
pure drug 
added 
(mg) 
Total 
amount of 
drug found 
(mg) 
% Recovery* 
±S.D. 
 
Tablets 
(Zospar) 
200 mg 
 
195.96  
 
20.00 
30.00 
40.00 
215.79 
225.59 
235.55 
99.13±0.21 
99.10±0.32 
98.97±0.29 
 
Tablets 
(Sparflo) 
200 mg 
 
195.80  
 
20.00 
30.00 
40.00 
215.59 
225.54 
235.34 
98.93±0.26 
99.16±0.28 
98.87±0.19 
 
*Average of five determinations ± SD 
 
  Table 29: Characteristics of determination of Sparfloxacin  
 
Wavelength of 
Maximum absorbance 685 nm 
Beer’s law limit (µg/ml) 
 2 to 60 
 Regression equation y= 0.0231x - 0.0067  
 Correlation coefficient (r2) 0.9999 
Sandell’s Sensitivity 
(µg cm-2/0.001 AU) 0.0433  
Molar absorptivity 
(lit/mole/cm) 9062 
% RSD 0.98 
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  Table30:Dissolution profile of sparfloxacin tablet  
    (zospar)at pH 7.6 
Estimated by UV Estimated by BMM 
Time in 
Minutes A290nm 
(Zospar
% 
Dissolutio
A 585nm 
(Zospar
% 
Dissolutio
15 0.711 49.86 0.193 49.61 
30 0.798 55.97 0.217 55.82 
45 0.875 61.38 0.239 61.35 
60 0.940 65.93 0.257 65.86 
75 0.959 67.27 0.260 66.92 
90 0.974 68.32 0.264 67.68 
105 0.958 67.20 0.259 66.42 
120 0.943 66.15 0.257 65.85 
Standard 
Solution
1.428 --------- 0.351 -------- 
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           Fig. 5.8 Dissolution profile of sparfloxacin tablet (zospar) at pH 7.6 
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Table 31: Dissolution profile of sparfloxacin tablet 
 (sparflo) at pH 7.6 
 
Estimated by UV Estimated by BMM 
Time in 
Minutes A290nm 
(Sparflo
% 
Dissolutio
A 585nm 
(Sparflo) 
% 
Dissolution
15 0.797    55.89 0.185 56.40 
30 0.876 61.43 0.245 62.82 
45 0.920    64.53 0.252 64.61 
60 0.965 67.68 0.264 67.68 
75 0.993 69.66 0.270 69.21 
90 1.014 71.15 0.277 71.02 
105 0.980 68.76 0.263 67.43 
120 0.972 68.17 0.259 66.41 
Standard 
solution 
1.283  ------ 0.351 ------ 
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Fig.5.9 Dissolution profile of sparfloxacin tablet (sparflo) at pH 7.6 
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Table 32: Dissolution profile of sparfloxacin tablets 
(zospar) at pH 4.0 
 
Estimated by (UV) Estimated by (BMM) 
Time 
in 
Minute
s 
A299nm 
(Zospar) 
%  
Dissolutio
A 585nm 
(Zospar) 
% 
 Dissolution
10 0.181 12.73 0.041 12.65 
20 0.647 45.57 0.148 45.25 
30 0.954 67.15 0.219 66.80 
40 1.093 77.04 0.229 69.92 
50 1.164 82.02 0.267 81.50 
60 1.169 82.37 0.270 82.17 
Standard 
Solution 
1.283 --------- 0.351 -------- 
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Fig.5.10 Dissolution profile of sparfloxacin tablet (zospar) at pH 4.0 
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  Table 33: Dissolution profile of sparfloxacin tablet  
    (sparflo) at pH 4.0 
                    
Estimated by  (UV) Estimated by (BMM)
Time in 
minutes A299nm 
(Sparflo) 
% 
Dissolution 
A 585nm 
(Sparflo
% 
Dissolutio
10 0.218 15.32 0.049 14.96 
20 0.661 46.57 0.152 46.32 
30 0.983 69.21 0.228 69.05 
40 1.137 80.13 0.263 79.60 
50 1.201 84.58 0.276 84.21 
60 1.205 84.89 0.278 84.65 
Standard 
Solution 
1.283 --------- 0.351 -------- 
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  Fig. 5.11Dissolution profile of sparfloxacin tablet (sparflo) at pH4.0 
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6. Summary 
 
? Fluoroquinolone antibacterial are introduced with latest 
classification, antimicrobial spectrum, general clinical indications, 
significant adverse effects and drug interactions. 
 
? Aim of present work is out lined. 
  
? Properties and analytical applications of dichlone, paraldehyde, 
crotonaldehyde and N-(1-Naphthyl) ethylenediamine 
dihydrochloride are reviewed and important reactions are 
discussed.  
 
? Drug profile and analytical methods for estimation of norfloxacin, 
ciprofloxacin and sparfloxacin are reviewed. 
 
? Spectrophotometric methods for the determination of norfloxacin 
and ciprofloxacin based on formation of purple colored chromogen 
in the reaction between the drugs, paraldehyde and dichlone are 
developed. Paraldehyde was used for the first time as analytical 
regent. 
 
? Using crotonaldehyde for the first time spectrophotometric 
methods are developed. The methods are based on formation of 
blue colored chromogen in the reaction between 
norfloxacin/ciprofloxacin, crotonaldehyde and dichlone. 
      
? A sensitive and reliable method for determination of sparfloxacin 
using Bratton-Marshal reagent is worked out.  
 
? Probable reaction mechanism for the proposed methods has been 
discussed. 
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? Effect of analytical factors on development of color is studied and  
Optimized. 
 
? The proposed methods are applied for estimation of norfloxacin, 
ciprofloxacin and sparfloxacin in bulk and their dosage forms like; 
tablet, ophthalmic solution and in combination with tinidazole in 
tablet. Results are compared with that of official/reported method. 
 
? The methods are validated for linearity between absorbance and 
concentration, Intraday-inter day precision and accuracy. The 
recovery study was performed to determined accuracy of the 
methods.  
 
? Dissolution test apparatus, methods and parameters affecting the 
dissolutions have been reviewed. 
 
?  Dissolution profile of two brands of sparfloxacin tablets has been 
studied at pH 7.6 (phosphate buffer) and pH 4.0 (acetate buffer), 
estimating the drug concentration by the proposed 
spectrophotometric method and UV spectrophotometry. 
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